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Abstract 
 Fibroin is a biopolymer obtained from the cocoons of the Bombyx mori silkworm that 
offers many unique advantages. In this thesis work, fibroin was processed into a regenerated film 
and examined for potential biomaterial applications. 
 The adsorption of bovine serum albumin onto the fibroin film was investigated to 
examine the biocompatibility of the film, and it was found that BSA adsorption capacity 
increased with an increase in BSA concentration. At 10 mg/mL of BSA, the BSA sorption 
reached 0.045 mg/cm
2
. This level of BSA is indicative of good blood compatibility and 
biocompatibility of the fibroin. 
 The gas permeabilities of oxygen, nitrogen, and carbon dioxide were tested for potential 
applications in contact lenses and wound dressings. Over a pressure range of 70 – 350 psig, the 
permeability of oxygen and nitrogen was 5 Barrer, while that of carbon dioxide ranged from 26 
to 37 Barrer. The oxygen transmissibility of the fibroin films prepared in this study was on the 
low end required for use in daily wear contact lenses, but sufficient to aid the healing process for 
use in wound dressings. 
 The permeability and diffusivity of four model drugs in the fibroin film was investigated 
for potential applications in controlled drug release. The permeability at higher source 
concentrations leveled out to 0.8 – 4.3 x 10-7 cm2/s depending on the drug tested. The diffusion 
coefficient determined from sorption experiments was approximately 1.8 x 10
-9
 cm
2
/s, while the 
diffusion coefficients from desorption experiments were determined to be 0.8 – 2.7 x 10-9 cm2/s. 
The magnitude of the drug permeability and diffusivity are consistent with many other controlled 
release materials, and the fibroin film showed good potential for use in controlled release.
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Chapter 1: Introduction 
 
Biopolymers are gaining interest in both research and industrial applications for their 
unique properties and advantages over synthetic materials. Evolved to serve wide ranges of uses 
in nature, biopolymers can display unique mechanical and chemical properties which are 
advantageous in many applications. Biopolymers may come from renewable and often 
sustainable sources, as compared to the fossil-fuel base of most synthetic polymers. As a result, 
interest in biopolymers over synthetic materials has grown significantly over the past decade due 
to increased environmental consciousness. Perhaps one of the largest advantages of biopolymers 
is that they are generally both biocompatible and biodegradable. This feature is of great 
importance in many biomedical applications, where materials are needed that do not provoke an 
immune response and have the ability to degrade within the body without adverse effects 
(Sionkowska, 2011). 
Biomaterials are derived from a wide range of sources, including many different plants 
and animals. Some of the major natural polymers studied for use in biomaterials include 
chitosan, collagen, keratin, elastin, and silk (Sionkowska, 2011). Silk has been used for decades 
in medical sutures, and even longer in textiles, but interest in silk has grown for use as a material 
in contact lenses, wound dressings, controlled release of drugs, and as a scaffold in tissue 
engineering (Altman et al., 2003, Minoura et al., 1990, Arai et al., 2004). Silk is produced by a 
number of different larvae in the order Lepidoptera, including silkworms, spiders, scorpions, 
mites, and flies, with each producing a unique variety of silk (Altman et al., 2003). Most of the 
world’s silk used for textile and other applications is produced by the domesticated Bombyx mori 
silkworm. Silk from the Bomby mori silkworm consists of two main proteins, fibroin and sericin. 
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Fibroin provides the main fibrous structure to the silkworm cocoon while sericin is a glue-like 
protein that holds the cocoon together. Both fibroin and sericin can be used on their own or in 
blends to produce membranes and films with unique chemical and physical properties (Gimenes 
et al., 2007). 
Biodegradation refers to the ability of a material to be broken down into simpler, more 
easily dealt with components, through a number of different biological processes, such as 
bacterial metabolism or enzymatic attack. In the body, foreign materials are biodegraded through 
a complex interaction between biological, chemical, and physical factors. The ability of a 
biomaterial to biodegrade into non-harmful degradation products is important for many 
applications. Biodegradability is important in tissue engineering scaffolds, and the rate of 
biodegradation should be equal to or less than the rate of tissue growth. It is also important in 
controlled drug release applications in which a drug-loaded material is implanted within the 
body. The rate of degradation affects the rate of drug release in some instances, and full 
degradation is useful to avoid surgery to remove the material once the treatment is over (Altman 
et al., 2003).  
Biocompatibility may also refer to the extent and severity of host response to a material 
being used in biological applications (Williams, 1999). A wide range of body responses are 
lumped under the concept of host response, including inflammatory or immune response, cell 
toxicity, thrombogenic response, and enzymatic response (Altman et al., 2003; Tang et al., 2009; 
Park et al., 2001). Thrombogenic response is a blood response in which circulating blood 
proteins and biomolecules adsorb to the foreign material and form a thrombus. A thrombus that 
becomes large enough and dislodges is known as an embolism, and can travel through the blood 
stream to the heart or brain and cause heart attack or stroke. Adsorption properties of 
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biomaterials should favour little to no thrombogenic response if they are to be used in the blood 
stream. 
Bovine serum albumin (BSA), a very well characterized protein derived from bovines, is 
often used as a model protein in scientific investigations. In addition to being well characterized 
and understood, BSA is low in cost and slow to denature, which makes it ideal for research 
(Avremescu et al., 2003). Serum albumins, including BSA, are major components of blood, and 
the adsorption behaviour of BSA onto biomaterials plays a major role in limiting thrombus 
formation (Van Enckevort et al., 1984; Pitt et al., 1986). This investigation will look into the 
adsorption behaviour of BSA onto a fibroin film to determine if the film is likely to display 
thrombogenic response or good blood compatibility. High surface coverage of BSA adsorbed on 
the fibroin film would limit the adherence of thrombus forming biomolecules such as fibrinogen, 
limiting thrombus formation on the material surface. The extent of BSA adsorption and surface 
coverage on the fibroin surface will therefore be used as an indicator of thrombogenic response 
and blood compatibility. 
Silk has long been used as a material for biomedical applications in the form of sutures. 
Because of the unique properties of silk (e.g. tensile strength, biocompatibility, and 
biodegradability), it has traditionally made for a popular material in sutures. However, silk has 
recently fallen out of favour for use in sutures as concerns over biological responses to silk have 
been raised and its biocompatibility questioned. Further research has shown that sericin in the 
silk is the likely cause of the unfavourable immunological response, and this has renewed 
interest in silk fibroin for use as a biomaterial (Altman et al., 2003). Fibroin is found to have a 
biological response similar to such other materials as polystyrene, and is now a popular choice 
for biomaterial applications (e.g. tissue-engineering scaffolds) (Sofia et al., 2001). Fibroin has 
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been used as a scaffold for anterior cruciate ligaments, hepatic tissue, reticular connective tissue, 
cartilage, and bone formation, among many others (Altman et al., 2002; Hu et al., 2006; Pra et 
al., 2006; Silva et al., 2008; Sofia et al., 2001). Other areas of interest for fibroin as a biomaterial 
include contact lenses, wound dressings, and drug delivery systems. 
Contact lenses and wound dressings need to meet a number of unique requirements. 
Contact lenses need to be biocompatible and inert in the eye, have good chemical and 
mechanical stability, have good wetting ability, display appropriate optical transmission, and be 
very oxygen permeable (Sashina et al., 2009).  Wound dressings need to be biocompatible, have 
good oxygen and moisture permeability, and should promote wound healing (Min et al., 2012). 
Both contact lenses and wound dressings require good oxygen permeability, and thus this 
investigation will determine the oxygen permeability of fibroin film to see if the permeability is 
suitable for either application. 
Controlled drug release is another biomaterial application that is receiving considerable 
attention. The goal of controlled release is to deal with the problems of traditional drug delivery, 
where a large dose is often administered at one time, causing a spike in the drug concentration in 
the body, after which the concentration will fall as the drug is degraded and removed from the 
body. The spikes can potentially reach harmful concentration levels, depending on the drug and 
dose, and the lows can decrease the concentration below a level in which it is effective. The 
concentration range in which the drug is safe and effective is known as the therapeutic window. 
Controlled release looks to mediate drug release by encapsulating or embedding the drug within 
a polymer matrix and the diffusion of the drug out of the polymer or the polymer matrix 
degradation is used as a way to control the drug release into the body (Langer and Peppas, 1981). 
The biocompatibility, biodegradability, mechanical properties, and ability to be formed into a 
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film make fibroin attractive as a material in controlled release systems (Dyakonov et al., 2012). 
The present work looks to determine the permeability and diffusion coefficient of four different 
model drugs – tetracycline-HCl, diltiazem-HCl, ciprofloxacin-HCl, and tetrahydrozoline-HCl – 
in a silk fibroin film to look into its applicability as a material for controlled release applications. 
 
1.1 Objectives 
Several applications for various types of fibroin films have been reported in the literature, 
mainly focusing on biomaterial areas. This thesis work will focus on investigating the potential 
of fibroin films for such applications. 
 The blood compatibility and thrombogenic response of the fibroin film will be examined 
to determine if the film will display good biocompatibility in biomaterial applications. Therefore, 
the adsorption behaviour of BSA onto the fibroin film will be determined. The fibroin film will 
be looked into as a material for contact lenses and wound dressings as well. As an initial check 
of feasibility, the gas permeability, with a main focus on oxygen permeability, will be 
determined to see how permeable the film is to gases. 
The potential of the fibroin film for use in controlled drug release will be examined by 
measuring the permeability and diffusivity of four different model drugs in the film. The 
permeability and diffusivity greatly determine the rate of release through the membranes, and 
knowledge of these parameters is of importance when designing controlled release systems. 
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1.2 Scope of Thesis 
This thesis covers several aspects relevant to the potential applications of silk fibroin films, 
including as a biomaterial for contact lenses and wound dressings, and in controlled release 
systems. 
Chapter 1 was an introduction to biopolymers, silk and silk fibroin, biodegradability, and 
biocompatibility. Biomaterial applications as contact lenses, wound dressings, and controlled 
release were also addressed. The objectives and aims of the thesis work were elucidated. 
Chapter 2 was a literature review and in depth analysis of the topics introduced in Chapter 1 and 
their related concepts. These topics include fibroin, with major a focus on its biodegradability 
and biocompatibility, bovine serum albumin and protein adsorption, gas permeability pertinent to 
contact lenses and wound dressings, and drug permeability and sorption and desorption kinetics 
related to controlled release. 
Chapter 3 outlined the materials and methods used for the fibroin film preparation, as well as 
experiments with BSA adsorption, gas permeability, drug permeability, and sorption/desorption 
kinetics. 
Chapter 4 presented the results of the research, and the trends and significance of the data were 
discussed. 
The main conclusions drawn from this work were presented in chapter 5, where the applicability 
of fibroin films for each of the tested applications was addressed. Recommendations for future 
work on the topics of this investigation were provided in chapter 6.   
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Chapter 2: Background and Literature Review 
 
 The aim of this thesis is to investigate a number of different potential applications for a 
novel silk fibroin film. Three different areas with respect to fibroin films are to be looked into: 
bovine serum albumin (BSA) adsorption, as a biomaterial in contact lenses and wound dressings, 
and as a material in controlled drug release. The BSA adsorption study determines the extent of 
BSA sorbed on the film, which has a correlation to the blood compatibility of the film. The 
permeability of the film to oxygen, nitrogen and carbon dioxide gases are measured to determine 
if the gas permeability is sufficient for use in contact lenses and wound dressings. For potential 
use in controlled release, the permeability and sorption kinetics of four different model drugs in 
the fibroin film are evaluated. The research findings from this thesis work will serve to guide 
future research on fibroin films for the desired applications. The following attempts to provide a 
general background and review prior work reported in the literature relevant to the thesis work. 
 
2.1 Fibroin 
Fibroin is a silk protein mainly derived from the cocoons of the Bombyx mori silkworm, 
along with the glue-like protein sericin. Sericin can be removed from the fibroin using a 
degumming process, to leave only the fibroin fibers. The main structure of fibroin is a repeating 
sequence of six amino acids, (Gly-Ser-Gly-Ala-Gly-Ala), which causes a homogeneous 
secondary structure in an antiparallel β-sheet conformation (Motta et al., 2002). Based on 
molecular weights, two major groups of fibroin proteins can be distinguished: the light one has a 
molecular weight of 25 kDa and the heavy one 325 kDa (Altman et al., 2003). While the 
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crystalline antiparallel β-sheet region in fibroin comprises about two-thirds of the protein, the 
amorphous region of the fibers represents about one-third of the protein. Together these regions 
provide the unique mechanical properties that silk fibroin displays (Cao and Wang, 2009). Table 
2-1 displays the mechanical properties of various types of silk. 
Table 2-1: Mechanical Properties of Silk (Altman et al., 2003) 
Material Ultimate Tensile 
Strength (MPa) 
Modulus of Elasticity 
(GPa) 
% Strain at Break 
Bombyx mori silk 
with sericin 
500 5-12 19 
Bombxy mori silk 
without sericin 
610-690 15-17 4-16 
Spider Silk 875-972 11-13 17-18 
 
In general silk has a combination of very high strength and elasticity. Fibroin also has excellent 
resistance to failure in compression (Altman et al., 2003). Fibroin is a natural block copolymer 
that contains hydrophobic and hydrophilic blocks. The hydrophobic blocks create the β-sheet 
conformation of the fiber through hydrogen bonding between the blocks, and these regions are 
responsible for the high fiber strength, insolubility, and thermal stability of fibroin (Bini et al., 
2004).  
 Other favourable properties of silk fibroin include biodegradability and biocompatibility. 
Fibroin is able to be degraded in vivo through enzymatic degradation, resulting in harmless 
degradation products that can often be used by nearby cells (Cao and Wang, 2009). The foreign 
body response and inflammatory cell adhesion to fibroin is low, which means fibroin displays 
good biocompatibility (Santin et al., 1999). Fibroin can be processed into many different forms 
allowing for use in many applications. Besides the fiber form, fibroin can be processed into 
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films, sponges, gels, membranes, tissue scaffolds, and powders (Cao and Wang, 2009). The 
combination of unique mechanical properties, biodegradability and biocompatibility results in 
potential uses of fibroin for different medical applications.  
 The extensive hydrogen bonding between the β-sheets in silk fibroin leads to great 
stability and insolubility in most solvents. Solvents containing high concentration of salts such as 
lithium bromide, lithium thiocyanate, calcium thiocyanate, and calcium chloride have been 
shown to interrupt the hydrogen bonding between the β-sheets, turning the fibroin to an 
amorphous random coil conformation that is water soluble. Fibroin in this state can be processed 
into many different forms, including films, sponges, hydrogels, microparticles and many more, 
after which the β-sheet crystallinity can be returned through multiple methods (Wenk et al., 
2011). Fibroin processed this way is referred to as regenerated silk fibroin. One of the most 
common processing methods involves dialyzing the fibroin-salt solution to remove the salt, then 
returning the β-sheet structure with methanol treatment. The novel processing method employed 
in this thesis is to use liquid-liquid extraction to precipitate the fibroin from the salt solution into 
ethanol, then dissolving the precipitated fibroin in formic acid, followed by evaporation of the 
formic acid, to form a uniform fibroin film. 
 
2.1.1 Biodegradability of Fibroin 
Biodegradation is the process by which a material is broken down to simpler components 
through such biological processes as bacterial metabolism or enzymatic attack. The 
biodegradability and rate of degradation play an important role in many applications. In 
controlled release, where a drug is encapsulated within a polymer membrane and implanted 
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under the skin, it would be advantageous if the membrane degrades with no harmful degradation 
products so surgical intervention to remove it is not needed. However, the material shouldn’t 
degrade prematurely, or excessively high quantities of the drug could be released within the 
body. In tissue engineering, the scaffold biomaterial should preferably degrade, but the 
degradation should be matched or exceeded by the growth of the tissue (Altman et al., 2003). 
In vivo biodegradation occurs via complex interactions between many different 
biological, chemical, and physical factors. For silk fibroin, proteolytic enzymes are the main 
factor for the degradation. Enzymes degrade silk fibroin through adsorption onto the fibroin 
surface, and then digest the material into amino acids through hydrolysis of the peptide bonds. 
Several enzymes are known to degrade fibroin, including chymotrypsin, actinase, and 
carboxylase (Cao and Wang, 2009). 
Research into the degradation of silk has been ongoing for decades. In order to elucidate 
the structure and amino acid sequence of fibroin, Lucas et al. (1957) used chymotrypsin and 
carboxypeptidase to hydrolyze the peptide bonds in fibroin. It was found that the degradation 
products of the fibroin contained short peptide chains composed mainly of the amino acids 
glycine, alanine, serine, and small amounts of tyrosine. 
The US Pharmacopeia’s criterion for a biodegradable material is that it ‘loses most of its 
tensile strength within 60 days’ (Altman et al., 2003). Depending on the form of the fibroin, it 
can either meet or fail this criterion. Fibroin fibers, such as those used in sutures, will degrade in 
a longer time frame than when fibroin is in a film or membrane form. Arai et al. (2004) studied 
the effects of enzyme degradation of fibroin fibers and films using several different enzymes. 
They found that after incubating fibroin with enzymes for 17 days the reduction in initial weight 
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of the fibers was negligible, while for the films the weight reduction reached as much as 64%. 
On the other hand, for the tensile strength of the fibers the breaking load of the fiber was found 
to be reduced from 4.68 N for the control to 3.14 N for the fibers incubated with protease after 17 
days, a reduction of approximately 33%. It was hypothesized that proteolytic degradation 
occurred in the films more readily than the fibers because the films are more amorphous and 
prone to swelling, allowing the enzymes greater access to cleavage sites. 
Wang et al. (2008) has shown that the biodegradability of fibroin in vivo can be modified 
through the use of different processing methods and variables. Three-dimensional fibroin 
scaffolds were prepared using either an aqueous or organic solvent, with varying fibroin 
concentrations and scaffold pore sizes. The fibroin scaffolds were implanted in rats and their 
degradation was monitored for up to a year. The scaffolds prepared using an aqueous solvent 
were shown to degrade completely within 2-6 months, whereas the scaffolds prepared using an 
organic solvent all persisted for over one year. It was also found that the scaffolds prepared using 
high fibroin concentrations and small scaffold pore sizes degraded slowly. These results are 
important for both fibroin tissue engineering and controlled release. For tissue engineering, the 
fibroin scaffolds can be modified to degrade at slower or faster rates depending on the rate of the 
specific tissue growth, and for controlled release the fibroin can be modified to degrade at 
different rates depending on the length of time needed for drug delivery and release kinetics 
needed. 
2.1.2  Biocompatibility of Fibroin 
 The concept of biocompatibility does not have a precise definition or even understanding 
as a great deal of research from a wide-range of disciplines is continuously changing what is 
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known about the concept. One commonly accepted definition of biocompatibility, known as the 
Williams definition, states that biocompatibility is “the ability of a material to perform with an 
appropriate host response in a specific application” (Williams, 1999). By this definition, the 
biocompatibility of a material is not an intrinsic material property, but dependent on the 
application and the host response. The host response covers a wide range of responses that the 
body will have to implanted foreign material. Some of these responses include inflammatory 
response, cell cytotoxicity of the material or the degradation products, enzymatic response, and 
thrombogenic response; these responses can either be localized or systemic to the whole body 
(Altman et al., 2003; Tang et al., 2009; Park et al., 2001). The host response may not be the same 
in different parts of the body, and so a material that may be biocompatible in one area for one 
application may not be biocompatible in another area for the same or a different application. 
General indicators of a biocompatible material are low and non-sustained inflammatory 
response, low cell toxicity, and low thrombosis formation. In order to determine the 
biocompatibility of a material, in vitro tests can be performed to see how the material interacts 
with various biomolecules and cells, followed by more comprehensive in vivo testing of animals 
and then humans. 
 Fibroin has long been used in medical applications in silk sutures. Although popular for a 
long time, silk sutures fell out of favour after research revealed high incidences of allergic 
response and sensitization to the sutures, as well as the introduction of synthetic materials with 
better biocompatibility. Altman et al. (2003) undertook a comprehensive review of the literature 
on this topic, and concluded that sericin contamination in the silk is the likely cause of the 
allergic response, and not the fibroin proteins. As a result, interest in fibroin as a biocompatible 
material in medical applications has greatly increased thereafter. 
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 Inflammatory responses to biomaterials involve complex interactions between the 
biomaterial and a large number of immune system biomolecules and cells. A main trigger of 
inflammatory responses involves the activation of the immune system protein C3 on the surface 
of the biomaterial. After adhesion to the biomaterial, a disulphide bond in the C3 will be cleaved, 
and this will cause a cascade of adhesion of leukocytes (white blood cells) and macrophages to 
the material surface. Leukocytes and other inflammatory cells are also able to adhere directly to 
the biomaterial if certain chemical or physical interactions are present, as well as if proteins such 
as fibrinogen or the antibody IgG are adsorbed to the surface (Santin et al., 1999).  
 Santin et al. (1999) studied the in vitro inflammatory response of fibroin films and 
compared it to polystyrene and poly(2-hydroxyethyl methacrylate), and they found that the 
adhesion of fibrinogen to fibroin was lower, while the adhesion of C3 and IgG were comparable 
to the other surfaces. The activation of C3 on fibroin was also investigated, and no activation was 
detected. The adhesion of immune cells such as macrophages to the surface was also 
investigated, and fibroin was found to have significantly lower adhesion of these cells than the 
two other surfaces. These results indicate that fibroin has low inflammatory response, which is a 
good indicator of biocompatibility in a material. 
 Cytotoxicity is the toxicity of a material or chemical to the cells with which they make 
contact. Cytotoxic materials may cause a number of harmful effects on cells, including cell 
necrosis and eventual lysis, cell death or apoptosis, or a decrease in cell growth and viability. 
There are a number of ways to monitor the cytotoxicity of a material. Microscopy can be used to 
inspect cell morphology, and differences in the cell membrane and organelles can indicate 
cytotoxic effects. Cell growth and viability can be monitored using various techniques, and a 
reduced growth or a decrease in cell viability is an indication of cytotoxicity. Another way to 
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measure cytotoxicity is to look at the expression of biomolecules such as RNA or various 
proteins, and decreased levels of these biomolecules in the cell are indicative of cytotoxicity 
(Tang et al., 2009). 
Tang and colleagues (2009) looked into the in vitro cytotoxicity of fibroin with 
hippocampal neurons. Extracts of fibroin and hippocampal neurons, as well as control extracts of 
hydroxyapatite with hippocampal neurons and organotin with hippocampal neurons were created 
and analyzed for cytotoxicity using several methods. The hydroxyapatite extract is the non-
cytotoxic control and the organotin is the cytotoxic control. The morphology of the cells was 
characterized, and the fibroin extract cells displayed good morphology with no significant 
differences from the hydroxyapatite, and significant differences from the organotin. Cell viability 
was measured, and once again the fibroin cells displayed no difference from the hydroxyapatite, 
but significant differences from the lowered cell viability of the organotin. The expression of 
mRNA and other proteins associated with hippocampal neurons was determined, and once again 
the fibroin displayed no differences from the hydroxyapatite but significant differences from the 
organotin in the levels of these biomolecules. All these results indicate that fibroin is not 
cytotoxic to hippocampal neurons. Similar cytotoxicity work was done by Yang et al. (2007) 
with rat dorsal root ganglia and fibroin, and they concluded that fibroin does not display any 
cytotoxic effects on these cells. These results indicate that fibroin displays low cytotoxic effects 
on cells, and are a further indicator of the biocompatibility of fibroin. 
Thrombosis is the formation of a blood clot through the aggregation of blood proteins 
such as platelets and fibrin. Thrombogenic response is an important reaction that prevents 
excessive blood loss when a blood vessel is cut or broken due to injuries. Without this response, 
even small cuts in the skin would result in continuous blood loss that could prove fatal if not 
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treated. A thrombus may also aggregate when a blood vessel is not injured, and if it grows too 
large it can restrict the flow of blood and oxygen downstream of the clot. A thrombosis that 
detaches from the vessel wall and travels through the body is known as an embolism, and can 
result in heart attack or stroke. The potential harmful effects of thrombosis make the 
thrombogenic response of a biomaterial that interacts with the blood a very important 
consideration. The process by which thrombosis occurs is complex and not completely 
understood. When a biomaterial first comes into contact with blood, plasma proteins adsorb at 
the polymer surface. The adsorbed proteins cause platelets to adhere to the surface, which causes 
a further cascade of platelet activation, aggregation, and fibrin polymerization (Pitt et al, 1986). 
A number of properties of the biomaterial influence thrombus formation, including surface 
properties such as smoothness, and various protein-polymer interactions such as charged 
functional groups and other electrostatic interactions, and hydrophobic or hydrophilic 
interactions (Park et al., 2001).  
A number of studies have been conducted on the thrombogenic potential of silk fibroin. 
Dahlke et al. (1980) looked into the thromboginicity of black-braided silk sutures and several 
other materials. They found that the silk sutures induced a noticeable thrombic response within 
the first 7 days of post implantation, after which the thrombus gradually declined, and after 56 
days only minimal thrombogenicity remained. Lee et al. (1998) studied the in vitro 
antithrombogenicity of silk fibroin and silk fibroin/s-carboxymethyl keratein (SCMK) blend 
films. The films were found to be relatively antithrombogenic, with lowest thrombus formation 
at 50/50 fibroin/SCMK blend. It was concluded that the blend films modified the polar surface 
free energy, which was caused by changes in the silk conformation from random coil to 
antiparallel β-sheet. The β-sheet conformation resulted in a heterogeneous structure and this 
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enhanced the films biocompatibility by increasing surface polar properties. Park et al. (2001) 
investigated both in vitro and in vivo thrombogenicity of silk fibroin films treated in methanol for 
differing periods of time. For films treated in methanol for 15 and 240 min, no thrombus 
formation in vivo was noticed in 1 and 14 days post implantation. For the film treated in formic 
acid, there was no thrombus formation after 1 day, but thrombus formation occured along the 
entire surface after 14 days. Longer methanol treatment times displayed greater transformation to 
a β-sheet structure and increased polar component to the film surface tension. As the treatment in 
increased, in vitro platelet adhesion increased. A discrepancy exists between the results of Lee et 
al. (1998) and Park et al. (2001), with the former showing decreasing thrombus formation with 
increasing β-sheet structure, and the later showing increasing platelet adhesion with increasing β-
sheet structure. Both studies used IR crystallinity index to determine the extent of β-sheet 
conformation. The crystallinity index values in Lee et al. (1998) was 0.3-0.5, while the values in 
Park et al. (2001) was 0.575-0.675. This may suggest that there could be a value that minimizes 
thrombus formation between the two ranges. Other potential interpretations of the discrepancy 
include incompatible comparisons between the experimental procedures, or experimental error in 
one or both of the studies.  
These studies indicate that silk fibroin generally has good antithrombogenic properties. 
Attention, however, should be paid to the form and conformation of silk fibroin, because any 
changes may result in have substantial differences on the formation of thrombus in vivo.  
Fibroin displays good biodegradability, low inflammatory response, and good 
antithrombogenic properties. These features are essential for biocompatible materials, and it is 
expected that fibroin will be a strong candidate material for many biocompatible applications. 
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2.2  Bovine Serum Albumin Adsorption 
 As an initial assessment of the biocompatibility of the novel fibroin film, adsorption 
testing with bovine serum albumin was undertaken in this study. Serum albumins are one of the 
most common blood proteins, and they play an important role in the protein adsorption sequence 
that results in thrombus formation. The adsorption of the blood protein fibrinogen on a material 
surface will cause platelet adhesion and accumulation that result in thrombus formation. Platelets 
do not readily adhere to serum albumin, so the adsorption of albumin on a material surface will 
help to prevent thrombus formation. The adsorption of fibrinogen on a material surface has a 
negative correlation to the amount of albumin already adsorbed on the material. Albumin also 
diffuses to the surface of a material faster than fibrinogen, and so the ability of albumin to adsorb 
to a material surface and not be dislodged by fibrinogen molecules is of importance (Pitt et al., 
1986). Kaelble and Moacanin (1977) have shown through surface energy analysis that the 
adsorption and retention of a plasma protein film allows for greater blood compatibility for a 
material. With the previous in mind, determining the adsorption capacity of BSA on the fibroin 
film will be an indicator of the thrombic potential and biocompatibility of the film. 
 
2.2.1  Serum Albumin 
Serum albumin is the most plentiful plasma protein in the blood of mammals, and serves 
a number of important functions. Albumin was identified as a major component of blood in 
1839, and everything from its structure, to its functions, to its physical properties have been 
studied extensively since then. The main functions of albumin include the regulation of osmotic 
pressure in blood, transporter of fatty acids, sequestration and transportation of bilirubin, and the 
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maintenance of blood pH (Peters, 1975; Carter and Ho, 1994). Albumin performs many other 
smaller functions as well, and has the ability to reversibly bind with a very large number of 
different ligands. 
Albumin levels in the blood are important to the overall health, with low albumin levels 
resulting in a number of negative effects. Typical albumin concentrations in blood are 5 g per 
100 mL. Although rare, chronically lowered levels of albumin can result in hyperlipidemia and 
chronic fatigue (Carter and Ho, 1994). Albumin proteins are simple peptide chains that contain 
approximately 580 amino acids in the sequence. Albumin has a large number of the charged 
amino acids aspartic acid, glutamic acid, and lysine, leading to polarity in the molecule. It is also 
characterized by a large number of amino acids with hydrophobic side chains. While the tertiary 
structure of BSA has yet to be confirmed, evidence suggests it is a prolate ellipsoid with two 
axes of 40 Å and the third axis of 140 Å (Carter and Ho, 1994). Important physicochemical 
properties of albumin include small size, high solubility, a net negative charge, and many ligand 
binding affinities (Peters, 1975). Table 2-2 lists some properties for human and bovine albumins. 
Table 2-2: Physicochemical properties of human and bovine albumins (Peters, 1975). 
Property Human Albumin Bovine Albumin 
Molecular Weight (Da) 66,248 66,210 
Dimensions (Å) 38 x 150 40 x 140 
Isoelectric Point 4.7 4.7 
Net Charge at pH 7 per 
albumin molecule 
-18 -18 
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Due to its physiological importance, abundance, ease of isolation, stability, and low cost, 
albumin has been used as a model protein in research. The adsorption of albumin on many 
different surfaces has been studied extensively. Table 2-3 summarizes some of the prior work on 
albumin adsorption. 
Table 2-3: Adsorption capacity of BSA for various materials. 
Membrane Adsorption (µg/cm
2
) Reference 
Poly(ethylene vinyl 
alcohol) 
0.1 – 0.55 (Avramescu et al, 
2003) 
Silicone Rubber 0.16 (Young et al., 1998) 
Poly(vinyl Chloride) 0.16 (Young et al., 1998) 
Polyethylene 0.16 (Young et al., 1998) 
Poly(ether urethane) 0.17 (Young et al., 1998) 
Stainless Steel 0.21 (Van Enckenort et al., 
1984) 
Regenerated 
Cellulose 
0.25 (Bornzin and Miller, 
1982) 
 
The adsorption of serum albumin on material surfaces and interfaces has long been 
shown to generally follow a Langmuir adsorption isotherm (Hitchcock, 1925). Langmuir 
isotherms are characterized by the adsorption of a monolayer at the surface, with the adsorption 
capacity increasing with increasing concentration until the monolayer covers the entire surface. 
Using the dimensions of the molecule adsorbed, a theoretical maximum adsorption capacity can 
be estimated for a monolayer. The theoretical maximum surface concentration for a monolayer 
of bovine serum albumin has been calculated as 0.25 µg/cm
2
 (Bowen and Hughes, 1990). 
However, adsorption does not have to be limited to a monolayer in practice. Materials that are 
highly hydrophobic can have attractive forces that are strong enough to attract proteins over as 
far as 140 Å away from the material surface, which could potentially allow for a multilayer two 
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to three proteins in thickness (Kaelble and Moacanin, 1977). Multilayers may also occur through 
protein-protein interactions for the layers past the initial surface layer (Bornzin and Miller, 
1982). It should be noted that a reported surface concentration greater than the theoretical 
maximum surface concentration does not necessarily indicate a protein multilayer, instead 
surface roughness may create a larger surface area on the microscopic level that is not accounted 
for in the observed surface area.   
 
2.2.2  Protein Adsorption 
 Adsorption occurs when components of a fluid phase in contact with a solid phase are 
transferred to and held by interactions with the surface of the solid. Adsorption of molecules to 
surfaces is mainly governed by two types of forces, van der Waals forces and electrostatic forces. 
For non-polar surfaces and molecules, adsorption is governed by instantaneously induced 
dipoles, typically known as London dispersion forces. When the surface is polar and the 
molecule is non-polar, the electric field on the surface can induce a dipole in the molecules that 
enhances their attraction. A molecule with a permanent dipole can similarly polarize a surface 
and increase the adsorption. Strong adsorption can also result when the surface and the molecule 
are both permanently polarized (LeVan et al., 1999). Proteins contain many different charged 
and polar amino acids, and this leaves many areas of the molecules permanently polar and often 
gives the molecule a net charge. The primary amino acid structure of a protein is not the only 
consideration with respect to adsorption, as the secondary and the folded or tertiary structures 
will determine whether the polar regions are exposed to the surface or tucked away in the centre 
of the folded protein. 
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 Silk has long been considered a material of interest for adsorption purposes. Linus 
Pauling (1945) studied the adsorption of water onto the surface of silk, and found that the 
number of water molecules adsorbed corresponded to the number of polar side chains in the 
protein. Since then the adsorption capabilities of silk fibroin have been investigated for a wide 
range of applications, including heavy metal removal, protein adsorption in food production, and 
fibroblasts for tissue engineering (Zhao et al, 2011; Baycin et al., 2007; Yamada et al., 2004). 
With a main repeating structure consisting of glycine, serine, and alanine, fibroin does not 
contain any charged amino acids to make the surface charged. Serine is considered an amino acid 
with a polar side chain, alanine is considered to have a hydrophobic side chain, and glycine can 
be either hydrophobic or hydrophilic (Voet and Voet, 2004). The adsorption behaviour of fibroin 
should therefore be composed mainly of hydrophobic and polar interactions. 
 For proteins interacting with a biomaterial surface, the affinity between the protein and 
the surface can be represented by an adsorption constant. There are two adsorption isotherms that 
protein adsorption data generally fit, the Langmuir and Freundlich isotherms (Young et al., 
1988). 
 The Langmuir isotherm assumes adsorption occurs in a monolayer on a homogeneous flat 
surface (LeVan et al., 1999). The Langmuir isotherm is given by Eqn (2-1): 
   
 
   
 
   
     
           (2-1) 
where, CS is the mass of protein adsorbed per unit area, Cb is the bulk protein concentration in 
the solution, M is the molecular weight of the protein, K and A are adsorption constants, and NA 
is the Avogadro’s number. 
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When CS is plotted against Cb, the Langmuir isotherm predicts that CS will continuously increase 
with increasing bulk protein concentration, until a plateau is reached when CS reaches the 
monolayer surface concentration. In Figure 2-1, the strongly favourable isotherm represents the 
behaviour of the Langmuir isotherm. 
 
 
 
 
 
 
 Although in many cases the adsorption of proteins on surfaces does not meet the 
assumptions behind the Langmuir isotherm, it has been found that the Langmuir isotherm still 
fits well. However, since the underlying assumptions are not met, the meaning behind the 
parameters A and K are questionable for these cases (Young et al., 1988). 
 The Langmuir isotherm is often used in a linearized form for data fitting. 
 
  
 
   
 
 
   
 
 
   
           (2-2) 
If the sorption data follows the Langmuir isotherm, a plot of 1/CS against 1/Cb should yield a 
straight line, from which the constants A and K can be determined from its slope and intercept. 
Figure 2-1: Adsorption isotherms (McCabe et al., 1993) 
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 The Freundlich isotherm is an empirical adsorption isotherm that can fit protein 
adsorption data. The Freundlich isotherm, also assuming adsorption occurs on a homogeneous 
flat surface, is given by Eqn (2-3): 
                                                                   
   
                                                                    (2-3) 
where a is a constant that’s a measure of the adsorption capacity, and 1/n is a measures the 
intensity of adsorption (Young et al., 1988). When Cs is plotted against Cb, the resulting isotherm 
will be similar to the ‘favorable’ isotherm in Figure 2-1. A linearized version of the Freundlich 
isotherm is also widely used for data fitting. The linearized form is given by Eqn (2-4): 
           
 
 
               (2-4) 
If the adsorption data follows the Freundlich isotherm, a plot of log(CS) against log(Cb) should 
yield a straight line from which the constants a and 1/n can be calculated. 
 In static sorption tests, the amount of protein adsorbed onto the membrane can be 
calculated based on mass balance from the difference in solution concentration that varies from 
the initial concentration to the equilibrium concentration. 
                                                  (2-5) 
where meq is the mass of protein adsorbed on the surface, Co is the initial protein concentration of 
the solution, Ceq is the protein concentration at equilibrium, and Vo is the volume of the solution, 
which remains constant over the course of the adsorption. 
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 A useful way to compare adsorption behaviour between membranes is to normalize the 
quantity adsorbed by either the mass or area of the membrane used. This will provide insight on 
whether the adsorption occurs on the surface only. For instance, using: 
  
   
 
                                             (2-6) 
where q is the equilibrium adsorption capacity, and A is the membrane area, one will be able to 
compare the adsorption amount per surface area. For films of same material but with different 
thicknesses, the area normalized sorption uptake can also reveal whether any protein molecules 
will penetrate to reach the interior of the film. 
 
 
2.3  Gas Permeability 
2.3.1  Contact Lenses and Wound Dressings 
 The recent findings on the biocompatibility and biodegradability of fibroin have 
increased interest for fibroin as a biomedical material. Two growing areas of interest for fibroin 
are (1) as a material in contact lenses, and (2) for use in wound dressings. Both applications 
require biocompatibility but also oxygen permeability (Sashina et al., 2009; Min et al., 2012). 
The permeability of oxygen and other atmospheric gases through the silk fibroin membrane was 
to be examined in this study to determine the potential of fibroin films as a material for contact 
lenses and wound dressings. 
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 The permeability of oxygen through contact lenses is of utmost importance for ocular 
health and comfort. Insufficient oxygen permeability in a contact lens can cause corneal edema. 
Corneal edema is caused when cells that normally remove fluid from the eye are damaged, 
resulting in corneal swelling and progressively cloudier vision (Wu, 2012). Holden and Mertz 
(1984) showed that if contact lenses have a high enough oxygen permeability, the residual ocular 
swelling after a nighttime sleeping with the lenses is no greater than sleeping without the lenses. 
 A wound dressing is a material placed over a wound to aid in healing and to help prevent 
infection. Successful wound dressings will control the moisture content of the wound to allow 
the transport of epithelial cells around the wound, prevent infection by acting as a barrier to 
bacteria, and absorb blood and other excess fluids from the healing process (Syzcher and Lee, 
1992). Wounds are healed in four main phases: inflammation, migration, proliferation, and 
maturation. During the inflammation phase, blood clots form over the wound, bacteria and debris 
start to be cleared away from the wound, and blood vessels dilate to increase blood flow. During 
migration, macrophages move about the wound clearing damaged tissue and other materials, and 
this movement starts fibroblast formation and collagen synthesis. The proliferation stage sees 
collagen form into structural strands and epithelial cells will migrate to and form tissue on these 
strands, closing the wound. The last stage continues with tissue repair, as well as increasing 
vascularity to the healed tissue (Syzcher and Lee, 1992). Oxygen plays a very important part in 
the wound healing process, and as such an important property of a wound dressing is adequate 
oxygen permeability to the site of the wound. The major role of oxygen at the site of a wound is 
to control the growth of anaerobic bacteria and reduce the risk of infection, as well as decreasing 
tissue necrosis. Many of the cells and processes in the wound healing process require oxygen, 
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and there are some evidences that suggest increased exposure to oxygen at the wound site helps 
to oxygenate wound tissue and aids healing (Rodriguez et al., 2008). 
 There is considerable interest in fibroin as a material in wound dressings for not only its 
biocompatibility but also because the material itself has been found to enhance wound healing. 
Human skin fibroblasts, an essential part of the wound healing process, are able to attach to and 
grow on fibroin fibers to a level that is comparable to or even greater than that of collagen 
(Minoura et al., 1995). Yamada et al. (2004) used a proteolytic enzyme to digest fibroin and 
examined fibroblast adhesion and proliferation of the resulting peptide fragments. They found 
that two N-terminal region peptides are mainly responsible for increased fibroin growth, and the 
two peptides have a synergistic effect when they are together, further increasing fibroblast 
growth more than the individual peptides.  Fibroin has also been shown to aid in the adhesion 
and growth of human keratinocytes, a skin cell responsible for reepitheliazation of wounds (Min 
et al., 2004). The adherence and growth of both fibroblasts and keratinocytes on fibroin should 
aid in the healing and healing time for wounds when used as a wound dressing. Roh et al. (2006) 
examined the healing capabilities of silk fibroin, alginate, and silk fibroin/alginate (SF/AA) 
blend sponges. These sponges as well as a gauze control were subjected to circular wounds 
surgically induced in rats, and the extent of regenerated epithelium, collagen deposition, and cell 
proliferation were examined. It was shown that these sponges significantly decreased wound 
healing time (by approximately 50%), increased collagen deposition, and increased cell 
proliferation compared to the gauze control. The SF/AA sponge also displayed slightly better 
healing capabilities than individual silk fibroin or alginate sponges. Min et al. (2012) showed that 
a silk fibroin sponge dressing impregnated with nano-Ag displayed impressive wound healing 
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capabilities and antibacterial activity, resulting in a decreased healing time of wounds as well as 
allowing for proliferation of a normal epidermal layer over the wound. 
 
2.3.2  Gas Permeation 
Mass transfer across a membrane will occur if there is a driving force that acts on one or 
more components of the systems. The driving forces may be the chemical potential gradients 
across the membrane caused by differences in pressure, concentration, temperature, and 
electrical potential. The movement of a component i caused by a gradient in chemical potential is 
described by Eqn (2-7) (Baker, 2004): 
            
   
  
                                         (2-7) 
where Ji is the flux of component i, dµi/dx is the chemical potential gradient of component i, and 
Li is a proportionality coefficient between the flux and chemical potential gradient. 
The chemical potential is expressed by Eqn (2-8). 
                               (2-8) 
where R is the gas constant, T is temperature, γi is the activity coefficient, xi is the mole fraction 
of component i, υi is the molar volume of component i, and p is the pressure. Assuming ideal gas 
behaviour, Eqn (2-8) can be integrated to give Eqn (2-9). 
     
                              (2-9) 
where ui
°
 is the chemical potential of pure component i at the standard state. 
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Gas permeation through a film may be governed by two different mechanisms depending 
on the pore size of the film. Permeation through porous films may be described by the pore-flow 
model, while permeation in non-porous films is governed by the solution-diffusion model. When 
the pores in a film are large enough, a driving force will cause convective transfer of the gas 
molecules through the film. For dense films a solution-diffusion mechanism will be responsible 
for permeation, which is considered to take place in the following steps (Baker, 2004): 
1.  Gas molecules travel from bulk to the material surface. 
2. Gas molecules adsorb and dissolve within the material. 
3. A concentration gradient across the material will cause the diffusion of the molecules 
from the high concentration side to the low concentration side. 
4. The gas molecules are desorbed on the low concentration side. 
5. The gas molecules travel from the surface to the bulk on the downstream side of the 
film. 
Based on this mechanism, gas transport through a material is influenced by gas solubility and 
diffusivity within the membrane. Based on the Fick’s law of diffusion, the following equation 
can be derived (Wijmans and Baker, 1995): 
   
         
       
 
 
            (2-10) 
where ci,o(m) is the concentration within the membrane at x = 0, ci,l(m) is the concentration within 
the membrane at x = l, l is the membrane thickness, and Di is the diffusivity coefficient of 
component i. 
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The concentration of a gas within the film is related to the gas pressure, and based on 
Henry’s law: 
                                       (2-11) 
where Si is the sorption or solubility coefficient of the gas in the film. 
 Substituting Eqn (2-11) into Eqn (2-10) gives: 
   
  
          
 
         (2-12) 
where Pi
G
 = DiSi is the permeability coefficient of the gas in the film. Eqn (2-12) allows the 
calculation of the permeability coefficient of a film with knowledge of the flux at a certain 
applied pressure and film thickness. The permeability coefficient indicates the capacity of a 
material to permeating gas, and it is useful when comparing gas permeabilities in different 
materials with different film thicknesses. 
 
2.3.3  Oxygen Permeability 
 Sufficient oxygen permeability is a requirement in contact lenses to prevent corneal 
edema, and in wound dressings to prevent the growth of anaerobic bacteria and aid in the healing 
process. For extended wear of contact lenses, the minimum oxygen transmissibility required to 
avoid corneal edema during overnight wear is 87.0 x 10
-9
 (cm·mL O2)/(s·mL·mmHg) (Holden and 
Mertz, 1984). Oxygen transmissibility is equal to the oxygen permeability divided by the film 
thickness, and it is essentially the same as the so called permeance conventionally used in 
membrane separation. For wound dressings, the critical oxygen permeability values are not 
Chapter 2 Background and Literature Review   
 
30 
 
available; however, based on the evidence for antibacterial and enhanced healing properties of 
oxygen at the wound site, a high oxygen permeability in wound dressings is desirable. 
 For regenerated fibroin films, the processing method will have an effect on the resulting 
polymer matrix and the resulting properties of the film. Treatment of fibroin films with methanol 
induces a change in the polymer matrix from an amorphous to a more crystalline structure 
dominated by anti-parallel β-sheets (Motta et al., 2002). Also it has been shown that the gas 
permeability of a material (e.g., oxygen, nitrogen, carbon dioxide permeability) changes as the 
material undergoes a structural change (Yasuda and Hirotsu, 1977). It is therefore important to 
examine the oxygen permeability of the fibroin films prepared using different methods, because 
differences in the structure or morphology of the polymer matrix will affect the gas permeability. 
 There are a few studies on the oxygen permeability of regenerated fibroin films. Minoura 
et al. (1990), who examined the dissolved oxygen permeability of silk fibroin films of varying 
crystallinities using an oxygen electrode, found that as the crystallinity of the film increased, the 
oxygen permeability decreased. At 20°C, the oxygen permeability ranged from 4-8 Barrer 
depending on the crystallinity of the film. Kweon et al. (2001) evaluated the dissolved oxygen 
permeability of silk fibroin/chitosan blend films, and they found that the oxygen permeability 
increased as the chitosan content in the film increased up to a maximum at 50/50 
fibroin/chitosan, and then slightly decreased with a further increase in the chitosan content. The 
permeabilities of the pure fibroin and pure chitosan films were found to be 0.249 and 0.395 
Barrer respectively, while the 50/50 fibroin/chitosan film was 0.579 Barrer. 
 Besides oxygen, the permeability of the fibroin film to the components of atmospheric air 
(i.e. N2 and CO2) is also of importance. The separation of oxygen and nitrogen from atmospheric 
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air and the removal of carbon dioxide from flue gases via membrane separation are receiving 
increased attention as alternatives to conventional separation methods. Oxygen/nitrogen gas 
separation is an energy intensive process typically involving cryogenic distillation. Membrane 
gas separation is typically an energy efficient and low operational cost process, and represents a 
potential alternative to cryogenic distillation for the separation of oxygen and nitrogen. Concerns 
over industrial greenhouse gas emissions, especially from fossil fuel based power generation, has 
made the separation and capture of carbon dioxide a top priority. Gas scrubbers using 
regenerated amine solutions are typically used for carbon dioxide separation, but membrane 
separation is a promising alternative (Liu, C. et al., 2005). To compete with traditional 
technologies, gas separation membranes must display high permeability and selectivity for the 
target gas.  
 
2.4  Controlled Release 
 The concept of controlled drug delivery was first recognized in the 1960s by Folkman 
when he noticed that rabbits fell asleep when a tubing circulating their blood was exposed to 
anaesthetic gases on the outside. This gave him an idea that a closed off tubing containing a drug 
could be implanted and would deliver the drug at a constant rate (Hoffman, 2008). Since then 
interest in controlled drug delivery has grown considerably in an attempt to solve some of the 
general dose-delivery problems present in traditional methods of drug delivery. One of the major 
problems solved by controlled release is that of the drug concentration within the body. With 
pills or injections, the drug concentration within the body will quickly increase after ingestion, 
followed by a decline as the body metabolizes or excretes the drug. If the drugs are toxic, the 
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initial spike in concentration can create risks to the patient. If the drug has a minimum 
therapeutic concentration, once the concentration drops below this level the treatment will no 
longer be effective and the rest of the drug within the body is wasted. Once the drug 
concentration is below this level, readministration is needed, starting the cycle over again. 
Controlled release aims to eliminate this problem by providing a more steady rate of drug release 
into the body within the therapeutic window (Langer and Peppas, 1981).  
One popular method to provide a sustained release of drugs within the body is slowly 
releasing capsules. The capsules may operate on a number of methods, including slowly 
dissolving coatings, or complexing the drug with other molecules to lower its solubility. While 
these methods have proven successful, they still suffer from a number of problems such as high 
patient-to-patient variability in release rates and the constant need for readministration (Langer 
and Peppas, 1981). Controlled drug release is expected to reduce this variability and to provide a 
longer time frame for drug release. 
There are many advantages with controlled release systems including (Langer and 
Peppas, 1981): 
1) Drug concentrations are maintained in a therapeutically effective range. 
2) Local administration of a drug and reduce harmful effects present in systemic 
administration. 
3) Drugs rapidly degraded in vivo are protected from degradation. 
4) Smaller, continuous doses may reduce side effects and patient discomfort. 
5) Fewer administrations should improve patient compliance 
6) Less wasteful of drugs and potentially more cost effective. 
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7) Long operating times, from days up to years. 
However, some potential disadvantages are present in these systems as well: 
1) Cytotoxicity or lack of biocompatibility for the material used or its degradation products. 
2) Surgical operations for implanting the system or removing a non-degradable system. 
3) Pain or discomfort from the implanted system. 
4) Potentially expensive material and manufacturing costs. 
5) Potential for leaks or system degradation resulting in large amounts of drug release. 
6) Drug release hard to stop should the need arise. 
The use of polymers in controlled release applications is now of great interest. In polymer 
systems, the rate of drug release is controlled by the release of the drug from the polymer, which 
can be manipulated through different polymers, configurations, and polymer-drug preparation 
procedures. To combat the potential problems of toxicity, lack of biocompatibility, and lack of 
biodegradability, biopolymers such as silk fibroin are of significant interest in controlled release 
applications. 
In polymeric systems, drug release may occur through different mechanisms. There are 
five common release mechanisms, diffusion controlled, chemically controlled, swelling 
controlled, osmosis controlled, and magnetically controlled. Diffusion controlled systems are the 
most widely used, and they rely on the drug diffusion out of either a polymer surrounded 
reservoir, known as membrane permeation controlled (MPC), or a polymer matrix, known as 
matrix diffusion controlled (MDC), to control the drug release (Jain et al., 2003). In chemically 
controlled systems, the drug is either distributed bound or unbound within the polymer matrix 
and degradation of the polymer matrix and the biodegradation of the polymer to control the drug 
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release. In swelling controlled systems, water penetrates a solid polymer matrix infused drug 
molecules, allowing a transition from a glassy to amorphous state, which lets the drug diffuse out 
of the matrix. Magnetically controlled systems have both drug molecules and magnetic beads 
dispersed in a polymer matrix, and upon exposure to an oscillating magnetic field will greatly 
increase the rate at which the drug is released from the matrix (Langer and Peppas, 1981). 
2.4.1  Fibroin and Controlled Release 
 Natural biopolymers tend to show both biocompatibility and biodegradability which are 
advantageous in controlled release systems. However, the material properties of many 
biopolymers cannot be modified sufficiently for most controlled release applications. For a 
material to be successful in implantable controlled release applications, it must possess a number 
of important material properties. The material must not only be biocompatible, it should also be 
biodegradable with no harmful degradation products. The biodegradability should be 
controllable. In addition, the material should have a compatibility with the drugs or biomolecules 
being delivered, and display controllable release kinetics (Pritchard and Kaplan, 2011). Silk 
fibroin appears to display all these properties, which makes it an ideal biopolymer for controlled 
release applications. Silk fibroin fibers and films display excellent biocompatibility and have 
unique and impressive mechanical properties (Altman et al., 2003). The mechanical properties of 
regenerated silk fibroin films can be modified by changing the crystallinity (Motta et al., 2002). 
Silk fibroin is biodegradable in vivo, has harmless degradation products of amino acids and small 
peptides, and the rate of biodegradation can be controlled from days to years through 
modification of the β-sheet crystallinity, processing solvent, silk concentration, and porosity 
(Lucas et al., 1957; Horan et al., 2005; Wang et al., 2005; Pritchard and Kaplan, 2011). Fibroin 
films and matrices are able to encapsulate and stabilize proteins and enzymes through 
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intermolecular forces between the silk and biomolecules, then release the proteins undenatured 
and the enzymes with full activity (Lu et al., 2010). Silk fibroin can be processed and used in 
drug release in many different formats, including unprocessed fibers, films, nanolayers, 
hydrogels, sponges, and microspheres (Pritchard and Kaplan, 2011). The mass transfer and 
release kinetics within regenerated fibroin materials can be modified by changing the β-sheet 
crystalline content (Karve et al., 2011). Drug diffusion within the fibroin can also be controlled 
by the polymer morphology and other properties such as molecular mass (Pritchard and Kaplan, 
2011). The drug release kinetics can also be modified by changing the degradation behaviour via 
the above mentioned, or through the co-release of proteinase inhibitors such as ethylenediamine 
tetraacetic acid along with the target drug to disrupt proteolytic activity (Pritchard et al., 2011).
 One of the oldest uses for silk fibers was in medical sutures. Choi et al. (2004) showed 
that it is possible to enhance fibroin sutures using controlled release to create an infection 
resistant suture. Degummed silk fibroin was hydrolyzed, then two antibiotics, doxycycline and 
ciprofloxacin, were applied to the fibroin. The treated fibroin showed zones of inhibition of 
bacterial activity several centimeters in diameter for at least 24 hours in blood-flow simulated 
conditions. These results indicate the possibility of short-term infection resistant sutures, or even 
long-term infection resistant sutures that release antibiotics as the sutures degrade in vivo. 
 Regenerated fibroin films have been investigated for controlled release using both matrix 
diffusion controlled and membrane permeation controlled systems. In MDC systems, the drug is 
added to the fibroin solution before the film is cast, and this provides a uniform distribution of 
the drug within the film matrix. Liu et al. (2009) loaded the anticoagulant drug heparin into a 
polyurethane/silk fibroin blend membrane and examined the effects of film thickness, drug 
loading, and composition on the release kinetics. A longer sustained release of heparin occurred 
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when membrane thickness was greater, when drug loading was higher, and for films with higher 
fibroin contents. For MPC systems, there has been research using both conventional films and 
nano-film coatings to surround the drug reservoir. Chen et al. (1994) examined the permeability 
of a conventional fibroin film between two liquid reservoirs to five model drugs. The fibroin 
membrane was found to be an amphoteric ion exchange membrane, and would exclude one 
positively charged drug, while negatively charged drugs would have their permeability decrease 
with increasing pH, and the permeability of neutral drugs was independent of pH. The tendency 
for silk fibroin to form strongly interacting β-sheets allows for it to be deposited in a novel layer-
by-layer nano-coating. This coating method can be utilized for controlled release applications. 
Wang et al. (2007a) coated several drugs and proteins with a silk nanolayer and examined the 
release kinetics in vitro. The coatings displayed excellent mechanical properties for the 
application, and the release kinetics could be modified by controlling the β-sheet crystallinity of 
the coating as well as the coating thickness. 
 Fibroin hydrogels have also been created for controlled release applications. Hydrogels 
are a network of linked polymer chains that swell considerably when water is introduced, and 
have the ability to retain water in the polymer matrix. Fang et al. (2006) impregnated a fibroin 
hydrogel with the morphine-like opioid buprenorphine and examined the release behaviour. They 
found that the hydrogels followed a zero-order release rate, and the release could be controlled 
by changing the fibroin concentration. It was also noted that polymer drug solution can be 
injected and form stable hydrogel matrices once inside the body. 
 Silk nano and microparticles have received considerable attention for drug release 
applications. These particles range in size from tens of nm to hundreds of µm in diameter. These 
particles can be loaded with drugs or other biomolecules and release within the body. There are a 
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number of methods used to prepare these particles, including emulsions, self-assembly, ionic 
gelation, spray drying, laminar jet, and PVA-silk casting and dissolution (Pritchard and Kaplan, 
2011; Chen et al., 2012). Yan et al. (2009) synthesized silk nano-particles 40-120 nm in diameter 
and cross-linked the particles with insulin. The silk/insulin particles showed greater in vitro 
resistance to digestion and increased stability in human serum, resulting in an increase in the 
half-life by 2.5 times that of normal insulin. Chen et al. (2012) prepared silk nanoparticles 200-
500 nm in diameter containing the anti-cancer drug Paclitaxel under mild conditions. Under 
some of the conditions tested, the nanoparticles released Paclitaxel for periods ranging from 9 
days to 2 weeks, indicating the potential for use in targeted cancer therapy. Wang et al. (2007b) 
encapsulated the model enzyme horseradish peroxidase within silk microspheres. The enzyme 
retained its activity during processing and release, while the kinetics of the release could be 
controlled by processing conditions such as exposure to NaCl and MeOH. One of the major 
difficulties with silk nano-particles and microspheres is the high surface area to volume ratio of 
small particles. This high ratio leads to greater degradation rates compared to other drug delivery 
methods, but further research is being performed to improve degradation performance (Pritchard 
and Kaplan, 2011). 
 
2.4.2 Membrane Permeation Controlled Diffusion 
 Reservoir systems in which diffusion through a membrane or film controls drug release 
have received much attention for their simplicity and their ability to achieve zero-order release 
kinetics. Zero-order systems are critical in controlled release applications because they provide a 
steady rate of release that does not change with time (Langer and Peppas, 1981). This steady rate 
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of release allows these reservoir systems to be designed to provide relatively constant drug levels 
in the body that are within their therapeutic windows. 
 Drug diffusion through a membrane follows three stages, as shown in Figure 2-2.  
 
 
 
 
 
 
 
 
The first stage is marked by an initial transient period in which the drug concentration profile 
within the membrane is established, which results in a “time-lag” (θ) in the permeation. The time 
lag is found from extrapolation of the pseudo-steady state data to the time axis. The time lag can 
be used to determine the start of the second phase, as the effects of the transient period can be 
considered to have diminished after three times the time lag (3θ). The second phase is pseudo-
steady-state permeation during which period of time the concentration gradient across the 
membrane is relatively constant. In the third and final stage, the permeation slowly decreases 
with time as the concentration on the donor side depletes or on the receptor side increases to the 
point that the concentration gradient decreases and eventually reaches zero. The second phase of 
Figure 2-2: Three stages of drug permeation through a membrane (Chen et al., 2010). 
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pseudo-steady-state permeation provides the desired zero-order kinetics (Chen et al., 2010). The 
pseudo-steady-state phase can be extended through several techniques, including loading solid 
drug in the reservoir past its solubility limit to maintain a constant reservoir concentration 
(Langer and Peppas, 1981).  
 The diffusion of a drug through the membrane can be described by Fick’s law, 
       
   
  
        (2-13) 
where Ji is the drug flux through the membrane, Dim is the diffusion coefficient in the membrane, 
and dCi/dx is the concentration gradient across the membrane. When the diffusion coefficient is 
independent of concentration and the membrane thickness is constant, Eqn (2-13) can be 
integrated to give Eqn (2-14) (Langer and Peppas, 1981). 
       
  
 
        (2-14) 
where l is the membrane thickness. This equation shows that, as briefly discussed earlier, a 
constant flux will result from a constant concentration gradient across the membrane. A nearly 
constant concentration gradient can be obtained by keeping the donor side concentration much 
higher than the receptor side concentration. 
 Successful controlled release reservoir systems rely upon the knowledge of drug and 
membrane parameters such as permeability and diffusivity to tailor the controlled release system 
to the needs of the patient. One of the most widely used methods to determine a drug 
permeability coefficient within a membrane is known as the “mass balance” method. This 
method utilizes a mass balance on drug permeation data between the donor and receptor 
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reservoirs that are separated by the membrane (Chen et al., 2010). If the initial receptor drug 
concentration was zero, a mass balance between the two reservoirs yields Eqn (2-15). 
                     (2-15) 
where VD is the volume of the donor reservoir, VR is the volume of the receiving reservoir, Co is 
the initial donor reservoir concentration, CD is the current donor reservoir concentration, and CR 
is the receiving reservoir concentration.  
 Eqn (2-16) gives the rate of permeation through the membrane, 
  
   
  
 
  
 
               (2-16) 
where A is the membrane area, and P is the permeability coefficient. Integrating Eqn (2-16) from 
t=0 to t=t yields, 
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)           (2-17) 
where mo (=VDCo) is the total amount of drug in the system, and Vt is the total system volume. 
Plotting the logarithmic term against time should yield a straight line from the slope of which the 
permeability coefficient can be found. 
 The mass balance method makes several assumptions: (1) the quantity of permeant within 
the membrane is negligible, and (2) the permeant is transferred through the membrane 
immediately from the donor side to the receiver side. These assumptions neglect the initial 
transient phase during which the concentration profile within the membrane is established. It is 
therefore important to use only the permeation data after the pseudo-steady-state phase has been 
established, otherwise the inclusion of the transient phase data will cause underestimation of the 
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permeability coefficient (Chen et al., 2010). Figure 2-3 illustrates the extent the inclusion of the 
transient phase will alter the slope and permeability coefficient. 
 
 
 
 
 
 
  
While the mass balance method is able to give an accurate estimation of the permeability 
coefficient, another approach is needed to estimate the drug diffusivity within the membrane. 
One method to determine diffusivity coefficients of drugs within the membrane is to use sorption 
and desorption kinetics for the drugs. 
 For the sorption and desorption of solutes on a flat sheet in which the solution 
concentration changes, Crank (1975) shows an equation to estimate the diffusion coefficient: 
  
  
   ∑
       
        
    ( 
    
  
  
)          (2-18) 
Figure 2-3: Extent of underestimation of permeability by the inclusion of the transient period (Chen et al., 2010). 
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Where D is the diffusivity coefficient, Mt is the amount sorbed into the sheet at time t, M∞  is the 
amount sorbed at equilibrium, α is ratio of the volumes of the solution and the sheet, and qn’s are 
the non-zero positive roots of Eqn (2-19). 
                                         (2-19) 
 To obtain the diffusivity coefficient using Eqn (2-19), non-linear regression can be used 
to fit the model to experimental data. D can be determined by minimizing the squared errors 
between the model predicted and experimental values of (Mt/M∞). 
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Chapter 3: Experimental 
 
3.1  Film Preparation 
 Bombyx mori silkworm cocoons were cut into small fragments, and washed in water to 
remove dirt and impurities. The cocoon fragments were degummed in deionized water at 95°C 
until all sericin was completely removed and only fibroin fibers remained. The fibroin fibers 
were placed in an oven at 50°C for three hours to remove excess water. 25 g of fibroin fibers 
were then completely dissolved in 100 mL of 9.5 M lithium bromide solution heated in a water 
bath to 90°C. The fibroin-LiBr solution was filtered to remove any residual particles. 
Approximately 5 mL of the filtered solution was then dripped slowly into 150 mL of well stirred 
ethanol, and this was repeated with fresh ethanol until the fibroin-LiBr solution was consumed. 
When dropped into the ethanol, the fibroin precipitates out into small particles, while the LiBr  
stays in solution. The fibroin particles were removed from the ethanol by filtration, and 
repeatedly washed in deionized water to remove any leftover lithium bromide. After all the LiBr 
had been removed, the fibroin particles were dried in an oven at 50°C. The dried fibroin particles 
were then dissolved in a well-stirred solution of 98% formic acid. The fibroin-formic acid 
solution containing 13-wt% fibroin was then cast in a petri dish, followed by evaporation of the 
solvent, leaving the fibroin film. The film thickness was controlled from film to film by coating 
the same mass of fibroin-formic acid solution for each film. After evaporation, the fibroin film 
was placed in deionized water to remove any residual solvent. Then the fibroin films were 
removed from the petri dish and stored in deionized water until use. To our knowledge, this is a 
novel method to prepare fibroin films without using the extremely time consuming dialysis 
process to remove the lithium salt from the fibroin. 
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 The fibroin film so formed was dense and homogeneous, with no pore network capable 
of convective mass transfer through the film. The film thickness was measured with a 
micrometer. The thickness of the water wet films were in the range of 25-50 µm. The films were 
flexible and they displayed good strength when swollen in water, but extremely brittle when 
completely dried of all water.  
 
3.2 Bovine Serum Albumin Adsorption 
  Batch adsorption experiments were performed with the prepared films using bovine 
serum albumin to examine the biocompatibility of the fibroin film. The bovine serum albumin 
was purchased from Sigma Aldrich Co. Ltd. Pieces of fibroin film were placed in 5 mL BSA 
solutions of initial concentrations ranging from 0.25 – 10 mg/mL, and left for 24 hours for 
equilibrium to be reached. The concentration of the initial solution and solution at equilibrium 
were measured using a Shimadzu UVmini-1240 UV-Vis Spectrophotometer at a wavelength of 
285 nm. BSA calibration curves were created at 285 nm to relate the absorbance of the solution  
to BSA concentration. For each sample the film mass was recorded after drying the films for 1 
hour to remove all water. The equilibrium BSA sorption uptake in the film was determined from 
the change in solution concentration and the film mass: 
                                    (3-1) 
where Co amd Vo are the initial BSA concentration and solution volume, respectively, Vf  is the 
final volume of the solution, and meq is the equilibrium uptake at a concentration Ceq.  
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3.3  Gas Permeability 
 Gas permeation experiments were performed using the prepared fibroin films. The pure-
gas permeability of oxygen, nitrogen, and carbon dioxide were measured at room temperatures at 
pressures ranging from 70 to 350 kPag. The permeation experiments were performed using an 
apparatus shown in Figure 3-1. 
 
 
 
 
 
 
 
 Pure oxygen (O2), nitrogen (N2), and carbon dioxide (CO2) were supplied by Praxair. The 
feed pressure was measured using a Cole-Palmer pressure gauge and controlled using a pressure 
regulator fitted to the gas cylinder. The pure gas was first humidified with water in a gas 
humidifier before reaching the permeation cell to maintain constant water saturation in the 
membrane. The humidified gas enters the permeation cell in which a water wet fibroin 
membrane had been placed on a porous metal support between two non-woven fabric supports. 
O-rings were used to ensure a tight seal between the permeation cell and the membrane. The 
retentate stream in the permeation cell was closed off after air initially present in the system was 
Figure 3-1: Gas permeability experimental apparatus. 
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completely purged out. The volumetric flowrate of the permeate stream through the membrane is 
measured using a bubble flowmeter assembled with a 1-mL pipette primed with Swagelok 
Snoop
®
 Leak Detector fluid. The volumetric flowrates of the permeate gas stream were 
determined from the movement of the bubble in the bubble flowmeter at steady state permeation. 
The system was purged between the testing of different gases. The gas permeability was 
calculated from the gas flux through the membrane at each applied pressure. 
3.4 Degree of Swelling 
The degree of swelling of the fibroin film in deionized water (Rsw) was determined at room 
temperature from the water uptake: 
    
      
  
              (3-2) 
where Wsw is the weight of the water swollen film, and Wd is the weight of the dry film. 
 
3.5  Controlled Release 
 The permeability and sorption/desorption kinetics of four different model drugs with 
fibroin films were investigated. The model drugs used were ciprofloxacin hydrochloride, (+)-cis 
diltiazem hydrochloride, tetracycline hydrochloride, and tetrahydrozoline hydrochloride. All the 
model drugs were purchased from Sigma-Aldrich Co. Ltd. and used as received, except for 
ciprofloxacin hydrochloride which was prepared by reacting ciprofloxacin (supplied by Fluka 
BioChemica Co. Ltd.) with excess hydrogen chloride in diethyl ether to form ciprofloxacin 
hydrochloride. The details of the ciprofloxacin hydrochloride formation can be found in Chen et 
al. (2010). All these drugs were water soluble in their hydrochloride forms, and the drug 
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solutions were prepared by dissolving the pre-determined drug quantity in deionized water. Drug 
solutions in concentrations ranging from 50-500 ppm were used in the controlled release 
experiments. The chemical structures of the four model drugs used are shown in Scheme 1. 
 
 
 
 
 
 
 
 
 
 
 
Diltiazem-HCl is a calcium channel blocker and vasodilator used in the treatment of high blood 
pressure and angina. Ciprofloxacin-HCl is a broad-spectrum antibiotic, typically used to treat 
respiratory, urinary tract, gastrointestinal, and abdominal infections. Tetracycline-HCl is a broad-
spectrum antibiotic commonly used to treat urinary tract and intestinal infections, as well as 
 
 
  
Scheme 1: Chemical structure of the four model drugs used. Top left – diltiazem-HCl; top right – ciprofloxacin-HCl; 
bottom left – tetracycline-HCl; bottom right – tetrahydrozoline-HCl. 
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acne, and was historically used in the treatment of cholera. Tetrahydrozoline-HCl is used in over-
the-counter eye drops to constrict the blood vessels of the eye and relieve redness (Karch, 2012). 
 
3.4.1  Drug Permeability 
 The experimental set-up for the drug permeability experiments is shown in Figure 3-2. 
There were 2 reservoirs; the donor reservoir was suspended partially in the receiver reservoir, 
with the fibroin film mounted on the bottom of the donor reservoir separating the reservoirs. The 
effective area of fibroin film separating the two reservoirs for drug transport was 11.3 cm
2
. The 
receiver reservoir was filled with 2 L of deionized water. At time zero, 80 mL of drug solution at 
a given concentration (ranging from 50-500 ppm) was charged to the donor reservoir. Both 
reservoirs were well stirred to minimize the liquid mass transfer boundary layer resistances. The 
absorbance of the solution in the receiving reservoir was measured every 5 minutes using a 
Shimadzu UVmini-1240 UV-Vis Spectrophotometer, and the absorbance values were converted 
to drug concentration using calibration curves created for each drug. The wavelengths used in the 
spectrophotomer were 236 nm for diltiazem hydrochloride, 213 nm for tetrahydrozoline 
hydrochloride, 314 nm for ciprofloxacin hydrochloride, and 356 nm for tetracycline 
hydrochloride. The permeability coefficients were determined from the resulting data using the 
Mass Balance method during pseudo steady state drug release. 
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3.5.2  Sorption/Desorption Kinetics 
 For the sorption experiments, water swollen fibroin films (dry mass 0.13-0.3 g; thickness 
25-50 µm) were placed in 50 mL of aqueous drug solutions of given concentrations (ranging 
from 100 to 500 ppm). The sorption uptake was monitored by measuring the drug concentrations 
in solution every 5 min using the Shimadzu UVmini-1240 UV-Vis Spectrophotometer until 
equilibrium was reached. Further, the drug-loaded films from the sorption experiments were used 
for desorption experiments by immersing each drug-loaded film into 50 mL of deionized water. 
The increase in drug concentration of the solution was measured every 5 minutes using the 
spectrophotometer until equilibrium was reached.  
Figure 3-4: Drug permeability experimental apparatus (Chen et al., 2010). 
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Chapter 4: Results and Discussion 
 
4.1  Degree of Swelling in Water 
 Membrane swelling affects physical properties of membranes (e.g. brittleness, strength 
and volume), as well as gas permeability. Water molecules between the polymer chains in a 
membrane will often increase mobility and free volume between the chains, thereby increasing 
the gas permeability. Therefore it is important to understand the degree of swelling of a material 
when considering applications in contact lenses and wound dressings where the material is in 
contact with a liquid solution. The degree of swelling of fibroin films was determined from the 
mass of water uptake in the films. 
 At equilibrium, the degree of swelling of the fibroin film in deionized water was 473% at 
room temperature. Comparatively, sericin/chitosan blend membranes have been observed to have 
a degree of swelling in the range of 265-272% (Eslami, 2011). The fibroin film swells 
significantly in water, which will greatly affect the gas permeability compared to a dry film. 
 
4.2 Bovine Serum Albumin Adsorption 
 The adsorption of BSA onto the fibroin film was investigated to determine the 
biocompatibility of fibroin, specifically its blood compatibility and likelihood of thrombus 
formation. The results for the equilibrium adsorption, at room temperature and pH 7, can be 
found in Figure 4-1.  
 Figure 4-1 shows the uptake of BSA on the fibroin films (in mg of BSA adsorbed per g of 
dry film) as a function of the BSA concentration in the solution at equilibrium. The adsorption 
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capacity of the fibroin film increases over the concentration range tested. Referring to the 
adsorption isotherms found in Figure 2-1, the BSA uptake onto fibroin film fell between the 
‘favorable’ and the ‘linear’ isotherms, with a slight downward concavity. 
 
 
 
 
 
 
 
Figure 4-1 shows large variability in the BSA uptake when taken on the basis of per unit 
mass of dry film. If the BSA is mainly sorbed to the surface of the fibroin film, then differences 
in the film thickness will affect the sorption uptake per mass of the film because of different 
surface areas per mass available for BSA uptake. Figure 4-2 shows the BSA uptake on the 
fibroin film per unit surface area (i.e. twice the film area), neglecting the surface area of the film 
edges. The area of the film edges represent <0.1% of the total surface area of the film, and can be 
neglected. 
Figure 4-1: Equilibrium uptake of BSA on fibroin film per mass of dry film 
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 Figure 4-2 shows a reduction in the variability in the BSA uptake when based on the 
external surface area of the film as compared to film dry weight. This shows that the BSA uptake 
on the fibroin film mainly occurs on the surface of the film. While it appears that much of the 
BSA is sorbed to the surface of the film, a small amount of the BSA may also have entered the 
film.  
 To further investigate whether the BSA sorption follows the Langmuir or Freundlich 
adsorption, linearized forms of both isotherms were plotted and linear regression was used to 
determine the best fit of each model. For the Langmuir isotherm, the inverse of the adsorption 
uptake was plotted against the inverse of the bulk equilibrium concentration, as shown in Figure 
Figure 4-2: Equilibrium uptake of BSA on fibroin film per unit surface area of film 
Chapter 4 Results and Discussion   
 
53 
 
4-3. For the Freundlich isotherm, the logarithm of the adsorption uptake was plotted against the 
logarithm of the equilibrium concentration, as shown in Figure 4-4. 
 
 
 
Figure 4-3: Experimental adsorption data plotted using a linearized Langmuir isotherm. 
 
Figure 4-3 shows a moderate linear trend using the linearized Langmuir isotherm and an 
R
2
 value of 0.763, but a close examination reveals some scatter in the data points at the far end of 
the range (i.e. at relatively low concentrations). This places undue importance on these data 
points, and can severely misrepresent the trend displayed by the majority of the data. The data at 
low concentrations display larger variance than the data at relatively high concentrations, and, 
with the influential nature of the later data points, may cause large errors in the parameter 
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estimation from regression analysis. The large variation is caused by a compounding of two 
effects. At very low concentrations, there is very little BSA uptake on the film, and this means 
very little change in solution concentration during the experiments. This means that any 
experimental errors present (i.e. from spectrophotometer calibration and measurement) greatly 
affect the calculated BSA uptake. In the linearized Langmuir model the reciprocal of the BSA 
uptake is used, and since the uptake at low concentration ranges are small and prone to large 
effects of error, the resulting reciprocal will display large variability. The parameter estimates for 
A and K were calculated from the slope and intercept of the linearized Langmuir model, and 
were found to both be negative. In the Langmuir isotherm, A represents the surface area per 
sorption site, and K is an equilibrium adsorption constant (Young et al., 1988). As such, negative 
values of these constants do not make physical sense, and indicate that the sorption of BSA onto 
fibroin film does not follow the Langmuir isotherm over the concentration range tested. 
Figure 4-4: Equilibrium adsorption data plotted using a linearized Freundlich isotherm. 
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 Figure 4-4 shows the Freundlich isotherm following a linear trend, with an R
2
 value of 
0.826. For the Freundlich model, the data are sparser at the beginning of the range (i.e. at 
relatively low concentrations), and more populated near the end of the range. While this may 
cause some leverage during the regression analysis for the low concentration points, the data are 
less spread than for the Langmuir isotherm, and as such the parameter estimates for the 
Freundlich model should be less error prone than the Langmuir estimates. 
  The model parameters for the Freundlich isotherm were estimated from the slope 
and intercept of the linearized Freundlich model, and are shown in Table 4-1. 
Table 4-1: Freundlich parameters for adsorption of BSA on silk fibroin. 
Freundlich Parameter 
A x10
3 
1/n 
3.5 1.203 
 
 Figure 4-2 shows BSA uptake increases as the equilibrium concentration increases, 
reaching 0.045 mg/cm
2
 (45 µg/cm
2
) at an equilibrium concentration of 10 mg/mL. The 
equilibrium uptake of BSA on the fibroin is greater than the theoretical maximum surface 
concentration based on monolayer surface adsorption of 0.25 µg/cm
2
 (Bowen and Hughes, 
1990). This high BSA uptake may be explained by discrepancies between the apparent and the 
effective fibroin surface area, multilayer sorption, or protein uptake within the film.  
The apparent surface area of the fibroin films was measured macroscopically, which does 
not account for surface roughness or micropores and therefore may underestimate the effective 
surface area. Using a microporous poly(ethylene vinyl alcohol) membrane with an effective 
surface area of 4 m
2
/g for BSA adsorption, Avramescu et al. (2003) found that BSA adsorption in 
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the range of 0.1 – 0.55 µg/cm2 corresponded to 4 – 22 mg/g dry membrane. Akgol et al. (2004) 
found that N-methacryloyl-(L)-histidine methyl ester beads with a BET surface area of 80.1 m
2
/g 
had a BSA adsorption capacity of 19.2 mg BSA/g. Lui and Bai (2005) found an adsorption 
capacity of 3.411 mg BSA/g dry membrane using a cellulose acetate/chitosan blend membrane 
with an internal surface area of 28.6 m
2
/g. These adsorption capacities are comparable to the 
results found for BSA adsorption onto fibroin films, which were found to be in the range 1 – 30 
mg/g dry membrane at equilibrium BSA concentrations from 0.25 – 10 mg/mL. The fibroin film 
is not microporous, and as a result the effective surface area for sorption will be determined 
primarily by external surface area. For sake of comparison, the fibroin film has an external 
surface area of approximately 0.06 m
2
/g dry weight, with BSA adsorption capacity of 1 – 30 
mg/g dry membrane. The fibroin film shows BSA sorption comparable to many other materials 
on a mass basis, but the film displays much greater sorption than the same materials on the basis 
of surface area. As mentioned, the high BSA uptake per film area may be caused by differences 
between the effective and apparent surface area, multilayer adsorption, or BSA uptake within the 
film.  
 The hydrophobic anti-parallel β-sheet regions present in silk fibroin could prove 
responsible for any potential multilayer adsorption. As mentioned previously, Kaelble and 
Moacanin (1977) showed the possibility of hydrophobic attraction over distances up to 140 Å. 
From Table 2-2, BSA has dimensions of approximately 40 x 140 Å, so under the right 
conformation up to three layers of BSA could potentially become adsorbed to the surface. 
Hydrophobic attraction could potentially be aided by protein-protein interactions between BSA 
molecules, allowing for greater retention upon the fibroin surface. 
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 At concentrations approximately 5 – 10 times less than blood albumin concentrations, 
BSA displays a decent level of adsorption onto the fibroin film. Decent albumin adsorption is an 
indicator of good blood compatibility for the fibroin film. Albumin adsorption on the fibroin 
surface should lead to lower levels of fibrinogen adsorption, thus limiting thrombus and 
embolism formation on its surface. This indicator of blood compatibility shows promise for this 
fibroin film in biocompatible material applications. 
 While albumin adsorption is one indicator of a material’s biocompatibility, more work is 
needed to confirm these findings. The strength of albumin adhesion on the surface is also 
important, so that the albumin molecules are not dislodged by fibrinogen. In vitro competitive 
adsorption experiments between albumin, fibrinogen, and other important blood biomolecules on 
fibroin should be performed to examine the sequential protein adsorption and blood response for 
the material. It should be pointed out that blood compatibility is only one indicator of 
biocompatibility, and to ensure complete biocompatibility of the film, appropriate experiments to 
determine inflammatory potential and toxicity should also be performed. 
 
4.3  Gas Permeation 
4.3.1  Permeability 
 The permeabilities of three gases, i.e., oxygen, nitrogen, and carbon dioxide, through 
water wet fibroin films were investigated, with particular attention being paid to the oxygen 
permeability for applications in wound dressings and contact lenses. The gas permeabilities were 
determined over a pressure range of 70 - 350 kPag. Figure 4-4 shows the gas flux through the 
film for the three gases, while Figure 4-5 shows the permeabilities. 
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Figure 4-5: Flux of O2, N2 and CO2 through fibroin film at varying pressures. 
Figure 4-6: Permeability of O2, N2, and CO2 through fibroin film at varying pressures. 
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 The fluxes of all the gases increase with an increase in the applied pressure. According to 
Eqn 2-13, the gas flux through a film should have a linear relationship with the applied pressure 
for solution-diffusion situations if the diffusivity and solubility of the permeant in the membrane 
are pressure independent. It is shown that oxygen and nitrogen follow linear pressure 
dependencies of permeation flux, and the pressure dependency of carbon dioxide flux is slightly 
nonlinear. Both oxygen and nitrogen display similar flux through the film, while carbon dioxide 
displays a larger flux. The differences between the fluxes of oxygen and nitrogen and the flux of 
carbon dioxide are caused by differences in the solubility and diffusivity of the gases within the 
membrane. Table 4-2 shows the Henry’s law constants and diffusion coefficients of the three 
gases in water. 
 
Table 4-2: Henry's Law constants and diffusion coefficients of O2, N2, and CO2 in water. 
 kH [M/atm]x10
3  D [µm2 s     
Oxygen 1.3
 
2000 
Nitrogen 0.63
 
1880 
Carbon Dioxide 34
 
1600 
 Henry’s law constants provided at 25°C from Sanders (1999). 
  Diffusion coefficients provided at 25°C from Crank et al. (1975). 
 
The solubility of carbon dioxide in water is much greater than the solubility of oxygen or 
nitrogen in water, while the diffusion coefficients are relatively similar. This difference in water 
solubility is likely the cause of carbon dioxide’s higher permeability than the permeabilities of 
oxygen and nitrogen. The fibroin film is water swollen during the permeability experiments, and 
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the presence of water in the membrane enables greater carbon dioxide solubility and thus greater 
flux and permeability. Oxygen is roughly twice as soluble and has a slightly greater diffusivity in 
water than nitrogen, but they exhibited a very similar flux through the fibroin. The solubility and 
diffusivity of the permeating gases in water are not the only considerations, since the solubility 
and diffusivity within the fibroin film matrix also play an important role. Differences between 
the solubility and diffusivity of oxygen and nitrogen within the fibroin matrix may offset their 
solubility and diffusivity in water, and this may explain the similarities in the flux and 
permeability. 
 The permeability of oxygen and nitrogen in the fibroin film are both approximately 5 
Barrer and do not change with pressure. The permeability of carbon dioxide is shown to be 26 – 
37 Barrer over the 70 – 350 kPag pressure range, with the permeability decreasing with an 
increase in the gas pressure. The permeability coefficient is the product of the solubility 
coefficient and the diffusion coefficient. A pressure-independent permeability coefficient will be 
observed when both the sorption and diffusion coefficients are pressure independent. 
 The oxygen permeability of 5 Barrer in the fibroin film compares closely to the oxygen 
permeability for fibroin film of 4-8 Barrer found by Minoura et al. (1990). The oxygen 
permeability values of Kweon et al (1990) of 0.249-0.579 Barrer in fibroin do not correspond as 
well with the results of this experiment, but are also not out of the range of plausibility. 
Differences in experimental technique may result in different permeability values, as the two 
research groups measured dissolved oxygen permeability, while this work used gas permeability. 
The film crystallinity and β-sheet content also play an important role in gas permeability. The 
crystallinity of the fibroin film created using the ethanol extraction technique used in this thesis 
work is not known. Differences in film crystallinity or other morphological differences between 
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the films may also be responsible for differences in the oxygen permeability values observed. To 
test this hypothesis it is suggested that the crystallinity of the fibroin film be quantified through 
appropriate analytical techniques such as FTIR spectroscopy, x-ray diffraction, differential 
scanning calorimetry, or NMR methods, and the crystallinity of the film compared to the fibroin 
films used by Kweon et al. (2001) and Minoura et al. (1990). 
 An oxygen transmissibility of 87.0 x 10
-9
 (cm·mL O2)/(s·mL·mmHg) is required for water 
wet hydrogel contact lenses to prevent corneal edema during overnight wear. Transmissibility 
(also known as permeance) is the ratio of the permeability coefficient to the effective membrane 
thickness. The fibroin film, with an effective water wet thickness of 26 µm and an oxygen 
permeability of 5 Barrer, corresponds to an oxygen transmissibility of 19.2 x 10
-9
 (cm·mL 
O2)/(s·mL·mmHg). The oxygen transmissibility of the fibroin film is below the critical 
transmissibility level required to prevent corneal edema during overnight wear. The critical 
oxygen transmissibility to prevent corneal edema is too large for many types of hydrogel lenses 
to achieve, so a compromise criterion of 34.3 x 10
-9
 (cm·mL O2)/(s·mL·mmHg) was suggested as 
this level leaves zero residual swelling of the eye shortly after eye opening (Holden and Mertz, 
1984). The fibroin film still does not meet this reduced criterion of oxygen transmissibility, but 
the gap has been greatly reduced. According to Holden and Mertz (1984), the oxygen 
transmissibility required to prevent corneal edema during daily wear conditions is 24.1 x 10
-9
 
(cm·mL O2)/(s·mL·mmHg). Once again the fibroin film does not meet this criterion. Based on 
these criteria, the fibroin film in its current state is not suitable for overnight or daily wear use as 
contact lenses.  
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Table 4-3: Oxygen transmissibility and permeability of polymers. 
Membrane Thickness 
(µm) 
Transmissibility 
(cm
3
(STP))/(s·cm2· 
mmHg)x10
9 
Permeability 
(Barrer) 
Reference 
Poly(vinyl alcohol) 90 3.9 3.5 Henry, 2006 
Hilafilcon silicone 36 22.2 8 Holden and 
Mertz, 1984 
2-
hydroxymethylmethacrylate 
186 18.4 34 Holden and 
Mertz, 1984 
(2-chlorophenyl)(2-
methylphenyl)methanol 
126 31.7 40 Holden and 
Mertz, 1984 
Bucrylate 74 16.2 12 Holden and 
Mertz, 1984 
Etafilcon A 137 133 182 Holden and 
Mertz, 1984 
Polymacron 111 7.2 8 Holden and 
Mertz, 1984 
Fibroin 26 19.2 5 This Work 
 
Table 4-3 shows some polymer hydrogel materials typically used in contact lenses, along 
with the results for fibroin from this work. Several materials show lower oxygen transmissibility 
than fibroin, but while contact lens materials with oxygen permeabilities lower than the 
minimum criteria set by Holden and Mertz (1984) are in use, they are being replaced by higher 
permeability materials as evidence shows chronic ocular problems associated with their use 
(Fonn et al., 2005). 
 While the fibroin film currently does not meet the oxygen permeability requirements for 
daily wear or overnight contact lenses, several different modifications to the film and its 
preparation may increase the oxygen permeability sufficiently to meet these requirements. 
Minoura et al. (1990) showed that decreasing fibroin film’s crystallinity increases the gas 
permeation, so methods that alter the β-sheet content of the fibroin film should be investigated. 
Treatment of fibroin films with methanol is often used to alter their crystallinity, with increasing 
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crystallinity resulting from longer treatment times. This suggests that exposure to ethanol may 
also increase crystallinity; shortening the length of exposure to ethanol in the fibroin extraction 
stage may result in lowered film crystallinity when preparing the films in the method used in this 
work. Another method to increase permeability is through blending fibroin with another 
biocompatible material. The blend film could potentially offer greater oxygen permeability than 
either of the pure materials. Potential materials could also be chosen to preferentially alter the 
resulting film properties to better fit other contact lens requirements, such as less brittleness or 
greater optical clarity. Through these or other modifications to the films, fibroin could potentially 
reach oxygen permeability values suitable for use in contact lenses. 
 There are no critical oxygen permeabilities required for wound dressings, but high 
oxygen permeabilities are generally considered beneficial to halt bacterial growth and aid the 
healing process. Sano et al. (2012) found that wound dressings with an oxygen permeance of 
91.4 x 10
-9
 (cm·mL O2)/(s·mL·mmHg) retained oxygen tension around the wound close to 
atmospheric levels, and showed significantly faster decreases in wound size and significantly 
thicker granulation tissue after seven days using a rat wound model compared to an effectively 
oxygen impermeable wound dressing. With an oxygen transmissibility of 19.2 x 10
-9
 (cm·mL 
O2)/(s·mL·mmHg), the fibroin wound dressing should allow high oxygen permeability and 
display very good oxygen tension around the wound. Fibroin’s good oxygen permeability and 
ability to aid the adherence and growth of cells responsible for wound healing suggest that 
fibroin films would be great assets in wound dressings. 
While oxygen permeability and cell adhesion and growth are important aspects in wound 
dressing, other issues with the fibroin film may need to be investigated. The fibroin film has a 
tendency to quickly lose moisture and become extremely brittle when exposed to the atmosphere 
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after being swollen with water. This moisture loss may have detrimental effects on wound 
healing. Cells will lose mobility around the wound surface and dressing, and eventually dry out 
the wound surface, limiting healing. Brittleness in the wound dressing may cause the dressing to 
crack and break apart if the patient moves around or pressure is otherwise applied to the 
dressing. One approach to deal with this problem is to blend the fibroin with another polymer 
that helps to retain moisture and avoid brittleness. If possible the blend material could also be 
chosen to further aid in the wound healing process, such as the fibroin/alginate blend wound 
dressing created by Roh et al. (2006). 
4.3.2  Selectivity for Gas Permeation 
 In gas separation applications, the permeability as well as the selectivity are important 
considerations. Selectivity represents the ability of a membrane to separate two gases. An ideal 
selectivity is measured by the ratio of the permeabilities of two pure gases: 
    
  
  
           (4-1) 
where αij* is the ideal selectivity, Pi is the permeability of component i, and Pj is the 
permeability of component j. Table 4-4 show the selectivities of the fibroin film for the permeant 
oxygen, nitrogen, and carbon dioxide gases: 
Table 4-4: Oxygen, nitrogen and carbon dioxide selectivities of fibroin film. 
Pressure (kPag) αO2/N2 αO2/CO2 αCO2/N2 
69 0.94 0.16 6.06 
138 1.03 0.18 5.78 
207 1.09 0.19 5.80 
276 1.07 0.20 5.45 
345 1.07 0.21 5.01 
 
Chapter 4 Results and Discussion   
 
65 
 
The fibroin film shows an O2/N2 selectivity of approximately 1 throughout the pressure range. At 
a selectivity of 1, no separation occurs. Since the fibroin film provides no separation between O2 
and N2, it would not be suitable as an O2/N2 gas separation membrane. The CO2/N2 selectivity 
decreases with increasing pressure, starting at approximately 6 at 69 kPag, and falling to 5 at 345 
kPag. A CO2/N2 selectivity greater than 200 is estimated as a requirement for an economically 
competitive polymer membrane for industrial applications dealing with flue gases (Granite and 
O’Brien, 2005). The CO2/N2 selectivity of the fibroin film is considerably less than the target 
selectivity of 200, and the fibroin film does not show potential for CO2 separation from flue 
gases, a subject that is important to greenhouse gas emission control. 
 
 
4.4  Controlled Release of Drugs 
4.4.1  Drug Permeability 
 The permeability of four model drugs, i.e., diltiazem-HCl, ciprofloxacin-HCl, 
tetrahydrozoline-HCl, and tetracycline-HCl, through a fibroin film was investigated for potential 
applications in controlled drug release. The experimental data on the drug permeation at different 
initial donor concentrations (50 to 600 ppm) are shown in Figure 4.7 – 4.10. 
 The permeation data show that as the drug concentration in the donor reservoir increases, 
the amount of drug permeated through the fibroin film also increases. This is consistent with 
Fickian diffusion through the film, in which the drug flux through the film is proportional to the 
concentration gradient across the film. Each permeation run shows an initial transient period in 
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which the rate of drug permeation gradually increases with time, followed by a pseudo steady-
state period in which the rate of drug permeation is constant. 
 The permeability coefficients of the drug at each concentration were calculated from the 
pseudo steady state permeation data for each trial. The pseudo steady state data can be subjected 
to analysis via the mass balance method if a reference time to is selected at the beginning of the 
pseudo steady state period (Chen et al., 2010): 
   (
       
      
)  
  
 
(
 
  
 
 
  
)              (4-2) 
where a = CR at t = to. Plotting F(t) = -ln[(mo-VtCR)/(mo-Vta)] against t will yield a straight line, 
and the permeability coefficient can be calculated from its slope.  
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Figure 4-7: Permeation data for Diltiazem-HCl at varying initial donor reservoir concentrations. 
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Figure 4-8: Permeation data for Ciprofloxacin-HCl at varying initial donor reservoir concentrations. 
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Figure 4-9: Permeation data for Tetrahydrozoline-HCl at varying initial donor reservoir concentrations. 
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Figure 4-10: Permeation data for Tetracyline-HCl at varying initial donor reservoir concentrations. 
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For the purpose of illustration, Figure 4.11 shows the F(t) vs t plots for the permeation data of the 
four model drugs at an initial donor reservoir concentration of 500 ppm, respectively. The 
permeability coefficients determined from the slopes of the F(t) vs t plots are shown in Fig 4.12. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-12 shows that at low initial donor reservoir concentrations, the permeability 
coefficient decreases quickly with an increase in the drug concentration. However, as the initial 
concentration increases above 200 ppm, the permeability coefficient will remain relatively 
constant with further increases in the drug concentration. As the initial donor concentration 
increases, quantity of permeated drug in the receiver increases, but the rate of the increase 
becomes slower, resulting in a reduction in the permeability coefficients. When increasing the 
initial concentration beyond a certain point (i.e., 200 ppm), the drug permeation rate is almost 
Figure 4-11: F(t) vs time plots for pseudo steady-state data. Initial drug concentration 500 ppm. 
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proportional to the concentration difference between the two reservoirs, leading to nearly 
constant permeability coefficients. 
 
 
 
 
 
 
 
 
 
 
 
 Diltiazem-HCl, and tetrahydrozoline-HCl display similar permeabilities in the fibroin 
film, and ciprofloxacin-HCl has a slightly lower permeability, while tetracycline-HCl displays 
the lowest permeability among the four model drugs tested here. The permeability in the 
concentration independent range (200 – 600 ppm) is approximately 4.1 x 10-7 cm2/s for 
diltiazem-HCl, 2.9 x 10
-7
 cm
2
/s for ciprofloxacin-HCl, 4.3 x 10
-7
 cm
2
/s for tetrahydrozoline-HCl, 
Figure 4-12: Permeability coefficients of four model drugs at varying reservoir concentrations. 
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and 0.8 x 10
-7
 cm
2
/s for tetracycline-HCl. Permeability is affected by many factors relating to the 
permeant, including molecular mass, solubility, hydrophobicity, net charge, and other chemical 
interactions. The molecular mass for the model drugs used are shown in Table 4-5. Examining 
the molecular mass and permeabilities of the four model drugs, there does not appear to be a 
clear correlation between the two. Tetrahydrozoline-HCl has the smallest molecular mass (236 
g/mol) and the largest permeability, and tetracycline-HCl has the largest molecular mass (480 
g/mol) and lowest permeability. However diltiazem-HCl also has a relatively large molar mass 
(451 g/mol), but exhibited a relatively large permeability. This indicates the permeability of the 
drug molecules in the fibroin film is not only determined by the diffusion rate (which is primarily 
determined by the molecular size of the permeant), and the solubility of the drugs in the film is 
also important to the permeability of the drugs. 
Table 4-5: Molecular mass and water solubility of model drugs. 
Drug Molecular Mass (g/mol) Solubility in Water 
(mg/mL) 
Diltiazem-HCl 450.98 590 
Ciprofloxacin-HCl 385.82 58.4
t 
Tetrahydrozoline-HCl 236.74 3 5  
Tetracycline-HCl 480.90 26.9
t 
 At 37°C from McClelland et al., (1991). 
  At 25°C from United States Pharmacopeia, (2009). 
tAt 40°C from Varanda et al., (2006). 
 
Table 4-5 lists the solubility in water of the four model drugs. A clear correlation can be seen 
between the water solubility and permeability within the fibroin film for each model drug. 
Diltiazem-HCl and tetrahydrozoline-HCl are highly water soluble, resulting in their relatively 
high permeabilities. Ciprofloxacin-HCl has a lower solubility in water, and a lower permeability 
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through the fibroin film. Tetracycline-HCl has the lowest water solubility and the lowest 
permeability.  
 The permeability values found in this experiment compare similarly to values from other 
researchers. Chen et al. (1994) looked at the permeability of five different drugs through a 
regenerated fibroin film using a similar reservoir setup. At pH 7, the permeabilities of 5-
Fluorouracil and Resorcinol were on the order of 10
-7
 cm
2
/s, benzyltrimethylammonium chloride 
was approximately 0.5 x 10
-7
 cm
2
/s, and sodium phenolsulfonate and ascorbic acid were on the 
order of 10
-9
 cm
2
/s. Chen et al. (2010) found that the permeability of ciprofloxacin-HCl through a 
chitosan membrane was approximately 5 x 10
-7
 cm
2
/s using a similar reservoir setup.  Eslami 
(2011) looked at the permeability of ciprofloxacin-HCl, diltiazem-HCl, and nitrofurazon through 
a chitosan/sericin blend membrane. Using the same mass balance technique, the permeability of 
ciprofloxacin-HCl was found to be approximately 1.5-3.0 x 10
-7
 cm
2
/s, diltiazem-HCl 
approximately 0.5 x 10
-7
 cm
2
/s, and nitrofurazon of approximately 13-17 x 10
-7
 cm
2
/s. The 
permeability values of the four model drugs in the fibroin film are all within the range shown in 
the literature from both similar membranes and similar drugs.  
 
4.4.2  Sorption Kinetics and Diffusivity 
 To determine the diffusivity of the four model drugs within the fibroin film, the sorption 
kinetics of drugs in the fibroin film were investigated at varying drug concentrations. Figure 4-13 
shows the equilibrium sorption uptake of the model drugs in the fibroin film at different drug 
concentrations in the solution. 
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 As expected, the equilibrium sorption uptake of each model drug into the fibroin film 
increases as the equilibrium drug concentration in the solution increases. Tetrahydrozoline-HCl 
shows the greatest sorption uptake in fibroin at approximately 20.2 mg/g (dry weight) of film at 
an equilibrium concentration of 383 ppm, compared to 17.6 mg/g (dry weight) of film at 435 ppm 
for ciprofloxacin-HCl, 12.5 mg/g (dry weight) of film at 514 ppm for diltiazem-HCl, and 7.8 
mg/g (dry weight) of film at 462 ppm for tetracycline-HCl. These data show that 
tetrahydrozoline-HCl and ciprofloxacin-HCl interact the most strongly with the fibroin film, 
followed by diltiazem-HCl, and then tetracycline-HCl with the weakest interaction. The drug-
fibroin interactions are important considerations in bulk-loaded films for drug delivery as it is 
indicative of how much drug can be loaded in the film. Strong interactions mean that more drug 
Figure 4-13: Equilibrium sorption uptake of four model drugs in fibroin film. 
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can be loaded into the film, but too strong interactions will keep the drug bound to the film and 
lower the quantity of drug that can be released by desorption, wasting potentially expensive drug. 
Figures 4-14 to 4-17 show the kinetics of sorption for the model drugs. The sorption data 
show the amount of drug sorbed to the film per gram (dry weight) of the film as a function of 
time at varying initial drug concentrations. The sorption kinetics show an initial transient period 
during which the drugs are quickly taken up into the fibroin film. The rate of drug uptake slows 
as it approaches its equilibrium point, and after approximately 100 minutes the equilibrium 
sorption uptake is reached and the amount of drug uptaken into the film no longer changes with 
time. As shown previously, the sorption uptake of drug within the fibroin film increases with 
increasing drug concentration, however, the drug concentration does not appear to affect the rate 
at which equilibrium is reached, which will be illustrated later.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-14: Amount of diltiazem-HCl sorbed into fibroin film at varying initial concentrations. 
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Figure 4-15: Amount of ciprofloxacin-HCl sorbed into fibroin film at varying initial concentrations. 
Figure 4-16: Amount of tetrahydrozoline-HCl sorbed into fibroin film at varying initial concentrations. 
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To compare the sorption kinetics and determine drug diffusivity within the film, the 
experimental kinetic data were normalized by dividing the quantity of drug in the film by its 
equilibrium sorption uptake. The model represented in Equation 2-18 is applicable for solute 
diffusion into a sheet from a solution of limited volume (i.e. changing solute concentration in 
solution) (Crank, 1975). Most sorption kinetics trials showed minimal changes in drug 
concentration throughout their course (i.e. <10%), but several trials with the largest sorption 
uptake (i.e. with tetrahydrozoline-HCl or ciprofloxacin-HCl) showed modest changes in drug 
concentration of up to 25%. The diffusion coefficients for each drug concentration were 
estimated using non-linear regression with the normalized sorption kinetics data and the model 
shown in Eqn 2-18. To determine the diffusivity at each concentration, the experimental data 
were fit to the model shown in Eqn 2-18. An initial diffusivity coefficient was guessed, then an 
Figure 4-17: Amount of tetracycline-HCl sorbed into fibroin at varying initial concentrations. 
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iterative numerical solving method was employed to change the diffusivity coefficient until the 
sum of square errors between the experimental data and model was minimized. For the purposes 
of illustration, Figure 4-18 shows the normalized sorption kinetics data and model predictions for 
ciprofloxacin-HCl at 500 ppm. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 4-18: Experimental sorption kinetics and model prediction for ciprofloxacin-HCl at 500 ppm. 
Figure 4-19: Conc. dependence of diffusion coefficients of four model drugs from sorption kinetics. 
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Figure 4-19 shows the model estimates of the diffusion coefficients based on the sorption 
kinetic data plotted against the initial drug concentration. The diffusivity based on sorption 
kinetics of each model drug in the fibroin film are approximately the same, and centered around 
2 x 10
-9
 cm
2
/s. No trend is observed between the diffusivity and the initial drug concentration for 
each of the four model drugs, indicating that the drug diffusivity within the fibroin film is 
independent of drug concentration. If the diffusivity is independent of the initial drug 
concentration, then the normalized sorption kinetics data at each concentration for an individual 
drug can be superimposed upon each other, and this is shown in Figure 4-20 to 4-23. Using non-
linear regression, the diffusivity for each drug was determined from the combined data set. Table 
4-6 lists the diffusivity values of the drugs so obtained, which represent the average diffusivity of 
the drug molecules in the fibroin film over the drug concentrations studied here. The model 
predictions using such diffusivity values are also presented in Figs 4-20 to 4-23, and there is a 
close agreement between the model calculations and the superimposed sorption kinetics data. 
This further supports the concentration independence of drug diffusion within the fibroin film. 
 
Table 4-6: Model drug diffusivity estimates based on combined sorption kinetics. 
 
 
 
 
 
 
Drug DSorption (cm
2
/s) x 10
9 
Diltiazem-HCl 1.86
 
Ciprofloxacin-HCl 1.81 
Tetrahydrozoline-HCl 1.83
 
Tetracycline-HCl 1.84
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Figure 4-20: Superimposed normalized sorption kinetics in fibroin film for diltiazem-HCl. 
Figure 4-21: Superimposed normalized sorption kinetics in fibroin film for ciprofloxacin-HCl. 
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Figure 4-22: Superimposed normalized sorption kinetics in fibroin film for tetrahydrozoline-HCl at varying concentrations. 
Figure 4-23: Superimposed normalized sorption kinetics in fibroin film for tetracycline-HCl at varying concentrations. 
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The diffusivity estimates based on sorption kinetics are very similar for each model drug, 
and are similar to drug diffusivities in other materials. Thacarodi and Rao (1993) examined the 
diffusivity of the anti-hypertensive drug nifedipine in a chitosan membrane, and found the 
diffusivity of the drug in the uncrosslinked membrane to be approximately 0.86 x 10
-9
 cm
2
/s. 
Eslami (2011) found the diffusivity of ciprofloxacin-HCl and diltiazem-HCl in chitosan/sericin 
blend membranes from both sorption and desorption kinetic data. The diffusivity for 
ciprofloxacin-HCl were found to be 3.2-7.6 x 10
-9
 cm
2
/s and 19.7-46.9 x 10
-9
 cm
2
/s, respectively, 
based on the kinetics data of sorption and desorption. The diffusivity for diltiazem were 5.9-10.1 
x 10
-9
 cm
2
/s and 11.9-23.7 x 10
-9
 cm
2
/s, respectively. Hines and Kaplan (2011) looked at the 
release mechanism, the effect of solute molecular mass and film crystallinity in the release of 
FITC-Dextran from regenerated fibroin films. They found that the release followed a diffusion 
model rather than an empirical exponential model, and that the diffusion coefficient decreased 
with increasing solute molecular mass as well as with increased crystallinity. The diffusion 
coefficients found to be in the range (0.30 – 4.74) x 10-9 cm2/s with the lowest diffusivity 
resulting from high solute molecular weight and film crystallinity, while the highest diffusivity 
was found with low molecular weight solute and low film crystallinity. Comparing the 
diffusivity results from this experiment against solute molecular mass does not show a 
decreasing diffusivity with increasing molecular mass. This is mainly because the molecular 
weights of the four model drugs are not substantially different from each other, and different 
drugs with different interactions being compared may confound any small difference the 
molecular weight causes.  
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4.4.3 Desorption Kinetics and Diffusivity 
 
 In principle, drug diffusivity within the fibroin film can also be determined from the 
desorption kinetics. Figure 4-24 to 4-27  shows the kinetics of desorption of the four model drugs 
from the fibroin film. The desorption data show the amount of drug desorbed from the film per 
gram (dry weight) of the film. At a higher initial drug loading in the film, the amount of the drug 
desorbed from the film increases. These results are easy to understand, since an increased initial 
solution concentration will increase the sorption uptake, and for the drug desorption, a larger 
amount of drug loading in the film will result in a larger amount of drug desorbed from the 
fibroin film.  
 
 
 
 
 
 
 
 
 
 
Figure 4-24: Amount of diltiazem-HCl desorbed from fibroin film at varying initial loading concentrations. 
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Figure 4-25: Amount of ciprofloxacin-HCl desorbed from fibroin film at varying initial loading concentrations. 
Figure 4-26: Amount of tetrahydrozoline-HCl desorbed from fibroin film at varying initial loading concentrations. 
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It needs to be mentioned that compared to the initial drug loading in the film, the amount 
of drug desorbed in a given amount of water (i.e. 50 mL) is less because desorption will cease to 
occur when the amount of drug remaining in the film is in equilibrium with the drug 
concentration in water. The amount of drug desorbed is 20-90% of the initial drug loading in the 
film, depending on the drug tested and the initial loading of the drug. This is in agreement with 
the equilibrium sorption isotherm shown in Fig 4-13. Table 4-7 shows the average relative 
amount of drug desorbed to the initial drug loading tested. 
Table 4-7: Average relative drug desorption to initial drug loading. 
Drug Average Relative Desorption 
Diltiazem-HCl 49% 
Ciprofloxacin-HCl 25% 
Tetrahydrozoline-HCl 39% 
Tetracycline-HCl 57% 
Figure 4-27: Amount of tetracycline-HCl desorbed from fibroin film at varying initial loading concentrations. 
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Tetracycline-HCl shows the largest amount of desorption, followed by diltiazem-HCl, then 
tetrahydrozoline-HCl, and finally ciprofloxacin-HCl which displays the least amount of 
desorption. This further shows that ciprofloxacin-HCl and tetrahydrozoline-HCl interact most 
strongly with the fibroin film which limits the amount of desorption that takes place. Conversely, 
tetracycline does not seem to interact with the film as strongly, and while this limits the initial 
loading onto the film, it leads to a higher fraction of the drug being released through desorption.  
Similarly to the sorption kinetics, the desorption kinetics data was normalized by dividing 
the amount of drug desorbed from the film by the amount of drug desorbed at equilibrium. Non-
linear regression was used with the normalized desorption data and the model (Eqn 2-18). For 
the purpose of illustration, the normalized desorption kinetics and model prediction are shown in 
Figure 4-28 for ciprofloxacin-HCl with an initial loading concentration of 500 ppm. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-28: Experimental desorption kinetics and model prediction for ciprofloxacin-HCl at 500 ppm. 
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Figure 4-29 shows the model estimates of the diffusion coefficients based on the 
desorption kinetic data plotted against the initial drug loading concentration. 
 
 
 
 
 
 
 
 
 
 
The diffusivity estimates based on desorption kinetics show much greater variability drug-to-
drug compared to the sorption kinetics estimates, but are still independent of concentration. 
Tetracycline-HCl shows the largest diffusivity of the four model drugs based on the desorption 
kinetics, while diltiazem-HCl and tetrahydrozoline show the lowest diffusivity. 
Since the diffusion coefficients based on the desorption kinetics appear to be independent 
of concentration, the trials at different concentrations can be superimposed upon one another for 
each model drug. Figures 4-30 to 4-33 show the superimposed desorption kinetics and model 
predictions for the four model drugs. 
 
 
Figure 4-29: Concentration dependence of diffusivity coefficients for the four model drugs from desorption kinetic data. 
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Figure 4-30: Superimposed normalized desorption kinetics for diltiazem-HCl. 
Figure 4-31: Superimposed normalized desorption kinetics for ciprofloxacin-HCl. 
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Figure 4-32:  Superimposed normalized desorption kinetics for tetrahydrozoline-HCl. 
Figure 4-33: Superimposed normalized desorption kinetics for tetracycline-HCl. 
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The superimposed plots for the desorption kinetics shows less agreement between the 
different concentrations for individual drugs than the sorption kinetics. There still does not 
appear to be any clear trend in the desorption kinetics with concentration for any of the model 
drugs. The diffusivity for each model drug based on the combined desorption kinetic data set is 
shown in Table 4-8. 
Table 4-8: Model drug diffusivity estimates based on combined desorption kinetics. 
 
 
 
 
 
 
Diltiazem-HCl and tetrahydrozoline-HCl both display lower diffusivity based on the 
desorption kinetics than the diffusivity based on the sorption kinetics. The lower diffusivity in 
desorption may indicate stronger interactions between the drugs and the film that makes for 
quicker sorption and slower desorption. Tetracycline-HCl displays higher diffusivity from the 
desorption kinetics than from the sorption kinetics. This may indicate weaker or even repulsive 
interactions between tetracycline-HCl and the fibroin film. These results are consistent with the 
earlier permeability results, in which diltiazem-HCl, ciprofloxacin-HCl, and tetrahydrozoline-
HCl all display greater permeability than tetracycline-HCl. Caution must be given to diffusivity 
estimates based on the desorption kinetics, since the model used to estimate the diffusivity is 
based upon sorption uptake, and the differences between sorption and desorption may make the 
model unreliable. In the latter case the drug concentration in the solution increases with time, 
Drug DDesorption (cm
2
/s) x 10
9 
Diltiazem-HCl 0.76 
Ciprofloxacin-HCl 1.82
 
Tetrahydrozoline-HCl 1.09
 
Tetracycline-HCl 2.73 
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which deviates from the assumption of negligible change in drug concentration, a condition for 
the model to apply to the desorption process. 
  
4.4.4  Solubility and Partition Coefficient for Drugs in Fibroin 
 A partition coefficient is the ratio of concentrations of a solute in two immiscible phases 
at equilibrium, which indicates the difference in solubility of the solvent in the two phases. The 
permeability of the solute is related to the partition coefficient and diffusivity. As a first 
approximation, 
               (4-3) 
where S is the partition coefficient. The partition coefficient can therefore be found from the 
ratio of the permeability and diffusivity. Figure 4-34 shows the partition coefficients for each 
model drug at varying drug concentrations. 
 
 
 
 
 
 
 
 
 
Figure 4-34: Partition coefficients of each model drug at varying drug concentration. 
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Since the diffusion coefficient is concentration independent, the partition coefficient follows the 
same trend as permeability. At low concentrations, the partition coefficient quickly decreases 
with increasing drug concentration, and as the concentration exceeds approximately 200 ppm, the 
partition coefficient becomes constant with further increases in drug concentration. For each 
model drug, the partition coefficients are well above unity (i.e. S >1), indicating that the model 
drugs are much more “soluble” in the fibroin membrane than in water. This is consistent with the 
sorption data shown in Fig 4-12, which also showed that the drug molecules were substantially 
“enriched” in the fibroin film. 
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Chapter 5: Conclusions 
  
Several properties of silk fibroin film were examined to determine the potential 
applicability of fibroin in several applications. The adsorption of bovine serum albumin to the 
fibroin film was conducted to explore its biocompatibility. The gas permeability of oxygen, 
nitrogen, and carbon dioxide was determined to gauge applicability of the fibroin film for uses in 
contact lenses and wound dressings where the gas transmissibility is of great interest. The 
permeability, diffusivity, and solubility of four model drugs in the fibroin film were determined 
for controlled drug release. The following conclusions can be drawn from this study: 
(1)  The fibroin film adsorbs bovine serum albumin at levels up to 0.045 mg/cm
2
 of film at an 
equilibrium concentration of 10 mg BSA/mL in solution. The BSA adsorption followed the 
Freundlich isotherm, with Freundlich parameters a = 3.5x10
-3
 and 1/n = 1.203. The levels of 
BSA adsorption suggest that the fibroin film will display good blood compatibility, which 
indicates strong potential for fibroin film in biocompatible material applications. 
(2) Over the pressure range (70-350 kPag) tested, oxygen and nitrogen display a constant 
permeability of 5 Barrer, while carbon dioxide permeability (ranging from 26-37 Barrer) 
decreases with pressure. The oxygen transmissibility of the fibroin film is 19.2 x 10
-9
 (cm·mL 
O2)/(s·mL·mmHg), just under the critical oxygen transmissibility of 24.1 x 10
-9
 (cm·mL 
O2)/(s·mL·mmHg) required to prevent corneal edema for daily wear contact lenses. While the 
fibroin film is not suitable for use in contact lenses in its current form as far as the oxygen 
transmissibility is concerned, fibroin film shows potential for use in wound dressings where the 
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oxygen permeability will elevate oxygen tension at the wound surface when used in wound 
dressings to aid in healing. 
(3) For the four model drugs (i.e., diltiazem-HCl, ciprofloxacin-HCl, tetrahydrozoline-HCl, 
and tetracycline-HCl), an increase in the initial source drug concentration increases the 
permeation rate of drug through the membrane. At low drug concentrations (i.e. <200 ppm), the 
permeability coefficient of the drug decreases with an increase in the drug concentration. At 
relatively high drug concentrations (200 – 600 ppm), the drug permeability becomes independent 
of drug concentration, with a permeability coefficient of 4.1 x 10
-7 
cm
2
/s for diltiazem-HCl, 2.9 x 
10
-7
 cm
2
/s for ciprofloxacin-HCl, 4.3 x 10
-7
 cm
2
/s for tetrahydrozoline-HCl, and 0.8 x 10
-7
 cm
2
/s 
for tetracycline-HCl.  
(4) During sorption and desorption experiments, increasing initial drug concentration 
increased sorption uptake into the fibroin, which in turn increased the amount of drug desorbed. 
Tetrahydrozoline-HCl shows the greatest sorption onto fibroin (20.2 mg/cm
2
) at an initial 
concentration of 500 ppm, compared to 17.6 mg/cm
2
 for ciprofloxacin-HCl, 12.5 mg/cm
2
 for 
diltiazem-HCl, and 7.8 mg/cm
2
 for tetracycline-HCl. From the sorption kinetics data, the drug 
diffusivity is determined to be 1.81 x 10
-9
 cm
2
/s for diltiazem-HCl, 1.83 x 10
-9
 cm
2
/s for of 
ciprofloxacin-HCl, 1.86 x 10
-9
 cm
2
/s tetrahydrozoline-HCl, and 1.84 x 10
-9
 cm
2
/s for tetracycline-
HCl. The fibroin film displays drug permeability and diffusivity at levels comparable to other 
drugs and materials, and it shows good potential for use in controlled drug release applications. 
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Chapter 6 – Recommendations 
 
 To further understand and develop fibroin film as a material for the applications 
investigated, further work should be undertaken and the following are recommended. 
1. The film crystallinity should be quantified through FTIR analysis and compared against 
that of the fibroin films reported in the literature. 
2. To further examine the blood compatibility of the film, competitive adsorption 
experiments between albumin, fibrinogen, and other blood constituent molecules on the 
fibroin film should be completed to determine which molecules adsorb preferentially, if 
any. 
3. The film crystallinity should be modified through alcohol treatment and the oxygen 
permeability investigated to determine if changes in the crystallinity will increases the 
permeability enough for use in contact lenses. 
4. The effects of different film blend formations on oxygen permeability for contact lenses 
are well as healing potential and brittleness in wound dressings should be investigated. 
5.  To understand the interactions between the drug and the film, the drug-loaded fibroin 
film may be analyzed and characterized through techniques such as FTIR and NMR 
spectroscopy. 
6. Different model drugs with differing characteristics such as hydrophobicity or water 
solubility should be investigated to further understand their effects on membrane loadings 
and release of the drugs in fibroin films. 
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7. The drug release may be controlled using many different forms of the fibroin, including 
bulk-loading of the drugs in films during preparation, microspheres, nano-particles, and 
hydrogels, and these should be investigated to identify the most effective release mode. 
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Appendix A: Sample Calculations 
 
Adsorption Calculations 
The solution concentrations were calculated from absorbance values, using a regression line fit to 
a calibration curve. 
                                                        
 
The adsorption capacity was determined from the change in initial and equilibrium 
concentration, the solution volume, and film mass. 
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Gas Permeability Calculations 
The first step in the gas permeability calculations was to find the gas flowrate from the 
flowmeter volume and time. 
  
 
 
 
        
      
          
   
 
 
 
The gas flux can then be calculated from the flowrate and the membrane area 
  
 
 
 
         
   
 
        
          
   
     
 
 
To calculate the permeability coefficient, the flowrate first needs to be converted to a standard 
flowrate at 0°C and 1 atm.
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The permeability coefficient can now be calculated from the standard flowrate, area, film 
thickness, and pressure. 
  
      
           
 
         
   
           
                       
     
      
     
         
            
 
Drug Permeability Calculations 
The first calculation needed is the mass of drug permeated at all the measurement times. This is 
found from the concentration in the receiving reservoir, and its volume. 
           
 
  
 
   
            
 
The amount of drug in the system can be found from the volume of the donor reservoir and 
initial concentration. 
                          
 
The permeability coefficient is contained within the following equation 
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Where α  is the concentration when long term permeation can said to have first occurred. 
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The permeability coefficient is therefore found from the slope of the logarithmic term versus 
time when only the long term permeation data is considered. 
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When the slope of this plot is found, the permeability coefficient can be found from the 
following. 
  
       
 
 
  
 
 
  
 
                 
        
 
     
 
      
 
 
    
          
   
 
 
 
Sorption/Desorption Kinetics Calculations 
First the experimental amount of drug adsorbed at time t divided by the amount of drug adsorbed 
at equilibrium as calculated from the concentrations. For adsorption: 
  
  
 
     
     
 
           
           
      
For desorption: 
  
  
 
  
  
 
    
    
       
 
Mt/M∞ was then found using the following model. 
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Where 
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And α is the ratio of the volumes of the solution and the film. 
For α = 25, the positive roots of tan(qn) = -αqn and pre-exponential term for the model are shown 
in Table A-1. 
Table A-1: Non-zero positive roots of tan(qn) = αqn, and pre-exponential term for α = 25 
qn Pre-Exp 
0 50 
1.544910 0.856549 
4.703886 0.093828 
7.848885 0.033741 
10.99194 0.017209 
14.13434 0.010409 
17.27644 0.006968 
20.41839 0.004989 
23.56025 0.003747 
    26.70204 0.002917 
    29.84379  0.002335 
    32.98551 0.001912 
 
The summation was truncated at n = 12, as the addition of more terms did not change the results. 
The resulting model was: 
M = 
 1-0.856549*exp(-(1.544910)^2*A*t)-0.0093828*exp(-(4.703886)^2*A*t)-…-0.001912*exp(-(32.98551)^2*A*t) 
where A = 4D/l
2
 
An initial value of A = 0.01 was guessed, which provided a model estimate of Mt/M∞. Estimates 
at each time interval were calculated, and the total sum of square errors between the 
model and the experimental value of Mt/M∞ was obtained. Using the Solver function in 
Microsoft Excel, A was varied until a minimum was found in the sum of square errors. The 
diffusivity that minimized the errors was taken as the drug diffusivity within the membrane 
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For Ciprofloxacin-HCl at 500 ppm, A = 0.01496 minimized the square errors, and the resultant 
output was: 
Time (min) M act M pred Mbar SE 
0 0 
-
0.034604045 -0.03460404 0.001197 
5 0.2929293 0.265244682 -0.02768461 0.000766 
10 0.4191919 0.397237295 -0.02195462 0.000482 
15 0.4949495 0.498010789 0.003061294 9.37E-06 
20 0.6313131 0.5805155 -0.05079763 0.00258 
25 0.6717172 0.649187866 -0.02252931 0.000508 
30 0.7020202 0.706566056 0.004545854 2.07E-05 
35 0.7474747 0.754549626 0.007074878 5.01E-05 
40 0.7979798 0.794684817 -0.00329498 1.09E-05 
45 0.8232323 0.828256879 0.005024555 2.52E-05 
50 0.8484848 0.856339343 0.007854495 6.17E-05 
55 0.8636364 0.879829909 0.016193545 0.000262 
60 0.8737374 0.899479429 0.025742056 0.000663 
70 0.8989899 0.929664908 0.030675009 0.000941 
80 0.9191919 0.950785942 0.031594023 0.000998 
90 0.9494949 0.965564508 0.016069559 0.000258 
100 0.959596 0.975905196 0.016309236 0.000266 
110 0.9747475 0.983140662 0.008393187 7.04E-05 
120 0.9747475 0.988203379 0.013455904 0.000181 
135 0.9747475 0.993095483 0.018348008 0.000337 
150 0.979798 0.995958813 0.016160833 0.000261 
165 0.989899 0.997634709 0.007735719 5.98E-05 
180 0.989899 0.998615604 0.008716614 7.6E-05 
195 0.9949495 0.999189718 0.004240223 1.8E-05 
210 0.9949495 0.999525745 0.00457625 2.09E-05 
225 1 0.999722421 -0.00027758 7.71E-08 
240 1 0.999837534 -0.00016247 2.64E-08 
255 1 0.999904909 -9.5091E-05 9.04E-09 
270 1 0.999944344 -5.5656E-05 3.1E-09 
285 1 0.999967425 -3.2575E-05 1.06E-09 
300 1 0.999980934 -1.9066E-05 3.64E-10 
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Appendix B – Supporting Data 
 
B.1 Bovine Serum Albumin Adsorption Data 
 
Table B-1: Bovine serum albumin adsorption data 
Membrane 
Area (cm
2
) 
Solution 
Volume 
(mL) 
Initial 
Concentration 
(mg/mL) 
Final 
Concentration 
(mg/mL) 
Mass 
Adsorbed 
(mg) 
Capacity 
(mg/cm
2
) 
57.2 5 4.49 4.34 0.74 0.013 
75.6 5 3.85 3.58 1.33 0.018 
79.8 5 3.08 2.81 1.35 0.017 
59.1 5 1.70 1.67 0.18 0.003 
108.4 5 1.57 1.50 0.34 0.003 
14.9 5 4.19 4.13 0.30 0.020 
36.5 5 3.38 3.23 0.75 0.021 
28.0 5 2.49 2.43 0.30 0.011 
34.0 5 1.00 0.98 0.09 0.003 
19.9 5 2.10 2.08 0.08 0.004 
28.6 5 2.93 2.83 0.49 0.017 
30.4 5 3.74 3.62 0.63 0.021 
9.5 5 9.62 9.55 0.34 0.036 
16.9 5 7.64 7.48 0.79 0.047 
12.2 5 6.77 6.68 0.46 0.038 
14.2 5 2.02 1.98 0.18 0.013 
16.9 5 3.03 2.96 0.39 0.023 
13.7 5 3.72 3.67 0.24 0.017 
14.3 5 4.49 4.42 0.32 0.023 
9.0 5 4.78 4.74 0.21 0.023 
79.7 5 5.87 5.36 2.55 0.032 
42.6 5 6.54 6.20 1.69 0.040 
26.2 5 7.15 6.97 0.87 0.033 
71.0 5 8.39 7.80 2.97 0.042 
31.0 5 9.35 9.10 1.24 0.040 
62.5 5 6.54 6.14 2.01 0.032 
67.9 5 6.71 6.30 2.04 0.030 
38.3 5 7.46 7.20 1.29 0.034 
49.7 5 7.50 7.22 1.40 0.028 
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83.1 5 1.76 1.57 0.98 0.012 
95.9 5 7.37 6.65 3.60 0.038 
98.0 5 5.61 5.00 3.03 0.031 
141.9 5 10.54 9.32 6.13 0.043 
63.1 5 6.04 5.66 1.94 0.031 
44.0 5 6.31 6.03 1.39 0.032 
77.0 5 8.64 7.97 3.31 0.043 
95.1 5 7.92 7.20 3.61 0.038 
29.8 5 5.48 5.36 0.58 0.019 
56.8 5 5.53 5.23 1.48 0.026 
95.1 5 8.08 7.35 3.67 0.039 
96.0 5 8.08 7.31 3.88 0.040 
 
 
B.2  Gas Permeability Data 
Oxygen Permeability 
Table B-4: Oxygen gas permeability data 
Pressure 
(psig) 
Temp (°C) Avg. Time 
(s) 
Volume 
(mL) 
Flux 10
5 
(cm
3
/cm
2
s) 
Permeability 
(barrer) 
10 26 232.0 0.05 1.25 0.57 
20 26 124.0 0.05 2.33 0.54 
30 26 79.0 0.05 3.66 0.56 
40 26 64.5 0.05 4.49 0.51 
50 26 48.4 0.05 5.98 0.55 
 
Nitrogen Permeability 
Table B-5: Nitrogen gas permeability data 
Pressure 
(psig) 
Temp (°C) Avg. 
Time (s) 
Volume 
(mL) 
Flux 10
5 
(cm
3
/cm
2
s) 
Permeability 
(barrer) 
10 26 252.5 0.05 1.32 0.61 
20 26 134.3 0.05 2.26 0.52 
30 26 90.0 0.05 3.37 0.52 
40 26 69.5 0.05 4.21 0.48 
50 26 53.3 0.05 5.57 0.51 
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Carbon Dioxide Permeability 
Table B-6: Carbon dioxide gas permeability data 
Pressure 
(psig) 
Temp (°C) Avg. 
Time (s) 
Volume 
(mL) 
Flux 10
5 
(cm
3
/cm
2
s) 
Permeability 
(barrer) 
10 26 35 0.5 8.42 3.68 
20 26 21.3 0.5 13.7 3.00 
30 26 14.2 0.5 20.5 2.99 
40 26 12.2 0.5 24.1 2.63 
50 26 9.9 0.5 29.3 2.56 
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B.3 Drug Permeability Data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B-1: Pseudo steady-state data for diltiazem-HCl. 
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Figure B-2: Pseudo steady-state  data for ciprofloxacin-HCl 
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Figure B-3: Pseudo steady-state data for tetrahydrozoline-HCl 
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Figure B-4: Pseudo steady-state data for tetracycline-HCl 
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B.4  Drug Sorption/Desorption 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B-5: Diltiazem-HCl sorption kinetics, 100 ppm. 
Figure B-6: Diltiazem-HCl sorption kinetics, 180 ppm. 
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Figure B-8: Diltiazem-HCl sorption kinetics, 325 ppm. 
Figure B-7: Diltiazem-HCl sorption kinetics, 225 ppm. 
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Figure B-9: Diltiazem-HCl sorption kinetics, 400 ppm. 
Figure B-10: Diltiazem-HCl sorption kinetics, 500 ppm. 
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Figure B-11: Diltiazem-HCl desorption kinetics, 100 ppm. 
Figure B-12: Diltiazem-HCl desorption kinetics, 180 ppm. 
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Figure B-13: Diltiazem-HCl desorption kinetics, 225 ppm. 
Figure B-54: Diltiazem-HCl desorption kinetics, 325 ppm. 
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Figure B-65 Diltiazem-HCl desorption kinetics, 400 ppm. 
Figure B-16: Diltiazem-HCl desorption kinetics, 500 ppm. 
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Figure B-17: Ciprofloxacin-HCl sorption kinetics, 100 ppm. 
Figure B-18: Ciprofloxacin-HCl sorption kinetics, 200 ppm. 
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Figure B-19: Ciprofloxacin-HCl sorption kinetics, 300 ppm. 
Figure B-20: Ciprofloxacin-HCl sorption kinetics, 400 ppm. 
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Figure B-21: Ciprofloxacin-HCl sorption kinetics, 500 ppm. 
Figure B-22: Ciprofloxacin-HCl desorption kinetics, 100 ppm. 
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Figure B-23: Ciprofloxacin-HCl desorption kinetics, 200 ppm. 
Figure B-74: Ciprofloxacin-HCl desorption kinetics, 300 ppm. 
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      Figure B-26: Ciprofloxacin-HCl desorption kinetics, 500 ppm. 
Figure B-85: Ciprofloxacin-HCl desorption kinetics, 400 ppm. 
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Figure B-27: Tetrahydrozoline-HCl sorption kinetics, 100 ppm. 
Figure B-28: Tetrahydrozoline-HCl sorption kinetics, 200 ppm. 
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   Figure B-30: Tetrahydrozoline-HCl desorption kinetics, 400 ppm. 
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Figure B-29: Tetrahydrozoline-HCl sorption kinetics, 300 ppm. 
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Figure B-31: Tetrahydrozoline-HCl sorption kinetics, 500 ppm. 
Figure B-32: Tetrahydrozoline-HCl desorption kinetics, 100 ppm. 
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Figure B-33: Tetrahydrozoline-HCl desorption kinetics, 200 ppm. 
Figure B-94: Tetrahydrozoline-HCl desorption kinetics, 300 ppm. 
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Figure B-105: Tetrahydrozoline-HCl desorption kinetics, 400 ppm. 
Figure B-36: Tetrahydrozoline-HCl desorption kinetics, 500 ppm. 
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Figure B-37: Tetracycline-HCl sorption kinetics, 100 ppm. 
Figure B-38: Tetracycline-HCl sorption kinetics, 200 ppm. 
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Figure B-39: Tetracycline-HCl sorption kinetics, 300 ppm. 
Figure B-40: Tetracycline-HCl sorption kinetics, 400 ppm. 
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       Figure B-42: Tetracycline-HCl desorption kinetics, 100 ppm. 
 
Figure B-41: Tetracycline-HCl sorption kinetics, 500 ppm. 
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Figure B-43: Tetracycline-HCl desorption kinetics, 200 ppm. 
Figure B-114: Tetracycline-HCl desorption kinetics, 300 ppm. 
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Figure B-125: Tetracycline-HCl desorption kinetics, 400 ppm. 
Figure B-46: Tetracycline-HCl desorption kinetics, 500 ppm. 
